{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1682,"total_is_capped":false,"direct_labels_cover":5,"predictions_cover":1682,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"fe77064d49b2","filters":{"topic":"Pharmaceutical Economics and Policy"}},"results":[{"id":"W2158310952","doi":"10.1016/s0140-6736(02)09096-7","title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","year":2002,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":882,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Incentive; Private sector; Public health; Pharmaceutical industry; Drug development; Developing country; Business; Market failure; Medicine; Disease; Neglected tropical diseases; Agency (philosophy); Economic growth; Public economics; Drug; Economics; Pharmacology","authors":[{"name":"Patrice Trouiller","is_ca":false},{"name":"Piero Olliaro","is_ca":false},{"name":"Els Torreele","is_ca":false},{"name":"James Orbinski","is_ca":true},{"name":"Richard Laing","is_ca":false},{"name":"Nathan Ford","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.157997367515106,"gpt":0.3480298722680117,"spread":0.1900325047529057,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01247767,0.001276718,0.003739554,0.003954051,0.0007661975,0.005413669,0.001799749,0.008459034,0.005470893],"category_scores_gemma":[0.02044174,0.0006572918,0.0007124402,0.006391279,0.005273481,0.007795529,0.002274117,0.005739344,0.001395464],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006548271,"about_ca_system_score_gemma":0.01610908,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005243772,"about_ca_topic_score_gemma":0.00886031,"domain_scores_codex":[0.9958096,0.001744111,0.0003264903,0.0002449706,0.001567076,0.0003078862],"domain_scores_gemma":[0.9745744,0.01873541,0.002630679,0.0005011825,0.002655505,0.0009029172],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002154755,0.0001525478,0.0006985575,0.0152274,0.0003320875,0.0003425586,0.0001376298,0.001740579,0.0004046404,0.1322034,0.1565007,0.6920444],"study_design_scores_gemma":[0.0002602761,0.0001679328,0.002546669,0.01792649,0.0002816925,0.001164493,0.000482014,0.001034945,0.0003864848,0.1991405,0.7765489,0.00005957215],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002809112,0.916916,0.0006162519,0.07892991,0.001122495,0.000006353589,0.0000543522,0.00001662448,0.002057221],"genre_scores_gemma":[0.006835463,0.9736611,0.0007286242,0.01544341,0.002651573,0.00001491916,0.00003642659,0.000008483173,0.0006199793],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01247767,"threshold_uncertainty_score":0.06598902,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2052972684","doi":"10.1016/j.mib.2003.08.003","title":"Why is big Pharma getting out of antibacterial drug discovery?","year":2003,"lang":"en","type":"review","venue":"Current Opinion in Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":501,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Drug discovery; Bureaucracy; Clinical trial; Drug development; Drug; Biology; Investment (military); Business; Process (computing); Intensive care medicine; Biotechnology; Pharmacology; Bioinformatics; Medicine; Political science; Law; Computer science","authors":[{"name":"Steven J. Projan","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.184830175105148,"gpt":0.3916683300344007,"spread":0.2068381549292527,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01261855,0.000671982,0.002652965,0.001584748,0.001042384,0.005262275,0.001440691,0.009258661,0.005925179],"category_scores_gemma":[0.02210283,0.0004862999,0.0009591568,0.00331813,0.004033292,0.009935349,0.001524549,0.009553388,0.002527882],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003690563,"about_ca_system_score_gemma":0.007044787,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003220812,"about_ca_topic_score_gemma":0.007922242,"domain_scores_codex":[0.9952233,0.001409004,0.0002819935,0.0003967252,0.002247662,0.0004413297],"domain_scores_gemma":[0.9644967,0.02422144,0.002864589,0.0007055913,0.005695254,0.00201647],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001923835,0.0001041881,0.001514855,0.005003542,0.000234278,0.0004464276,0.0002133771,0.0004798453,0.000942593,0.05595762,0.293525,0.6413859],"study_design_scores_gemma":[0.0001231557,0.0001723216,0.00451396,0.00472321,0.0001765636,0.001038388,0.0006017264,0.0004332959,0.0005177788,0.09561288,0.8920181,0.00006851678],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009857572,0.6173709,0.00130636,0.3667877,0.00594929,0.00001663286,0.00006533085,0.00006166905,0.007456383],"genre_scores_gemma":[0.0214057,0.7502159,0.002293928,0.204535,0.01621864,0.00003895737,0.00006713785,0.00005447479,0.005170221],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01261855,"threshold_uncertainty_score":0.06673402,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1970577443","doi":"10.1016/j.healthpol.2010.12.002","title":"The cost of drug development: A systematic review","year":2011,"lang":"en","type":"review","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":497,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"York University; University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Audit; Citation; Actuarial science; Medicine; Cash; Transparency (behavior); Confidentiality; Accounting; Business; Computer science; Finance; Library science","authors":[{"name":"Steve Morgan","is_ca":true},{"name":"Paul Grootendorst","is_ca":true},{"name":"Joel Lexchin","is_ca":true},{"name":"Colleen Cunningham","is_ca":true},{"name":"Devon Greyson","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2564027925749183,"gpt":0.4341284522402911,"spread":0.1777256596653727,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007894718,0.001153641,0.005582831,0.007748378,0.0002441222,0.00215542,0.001328803,0.001941418,0.006247988],"category_scores_gemma":[0.05153075,0.0009056251,0.00467618,0.0106052,0.000799925,0.002142851,0.001247671,0.00169951,0.0003385746],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00511996,"about_ca_system_score_gemma":0.009970062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00848294,"about_ca_topic_score_gemma":0.02535588,"domain_scores_codex":[0.9908303,0.003474539,0.002070041,0.0005043703,0.002879421,0.0002413995],"domain_scores_gemma":[0.9586938,0.03043332,0.007353634,0.0004799692,0.002649416,0.0003898666],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0009666959,0.0000543108,0.003145833,0.6865373,0.02883813,0.0002974583,0.00005792017,0.001263348,0.000166925,0.002850686,0.0206358,0.2551857],"study_design_scores_gemma":[0.001862126,0.0004976277,0.02097154,0.6152533,0.1925066,0.002165462,0.0002763481,0.001076402,0.0005236758,0.00686019,0.1578905,0.0001163753],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004061197,0.9979462,0.0001415301,0.000643978,0.0001329596,0.00003833554,0.0003824652,0.000003972241,0.0003044732],"genre_scores_gemma":[0.01016863,0.9885952,0.0003804742,0.0004005536,0.0001721561,0.00005735108,0.0001258295,0.00000383276,0.00009593312],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00848294,"threshold_uncertainty_score":0.0417518,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1989247444","doi":"10.1001/jama.2008.758","title":"Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease","year":2008,"lang":"en","type":"review","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":430,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging; Agency for Healthcare Research and Quality","keywords":"Medicine; Randomized controlled trial; Jadad scale; Medical prescription; Bioequivalence; Generic drug; Brand names; Clinical trial; MEDLINE; Context (archaeology); Drug; Internal medicine; Pharmacology; Advertising","authors":[{"name":"Aaron S. Kesselheim","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1798119531198471,"gpt":0.3666103435232169,"spread":0.1867983904033698,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1254313,0.001344732,0.007954586,0.01654962,0.001133307,0.007359863,0.002619462,0.004680176,0.003860711],"category_scores_gemma":[0.4993652,0.001107092,0.006227613,0.01385206,0.003461264,0.006264337,0.001901196,0.002545943,0.0004771988],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003774816,"about_ca_system_score_gemma":0.008450656,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001143556,"about_ca_topic_score_gemma":0.001990357,"domain_scores_codex":[0.7768177,0.09730595,0.0849719,0.007793874,0.03212457,0.0009859579],"domain_scores_gemma":[0.2919272,0.5383238,0.129632,0.008226328,0.03004456,0.001846145],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.006008819,0.0001557521,0.01865782,0.7898102,0.03941024,0.0004583082,0.001081774,0.0003172372,0.001303798,0.002643442,0.01247003,0.1276826],"study_design_scores_gemma":[0.01121753,0.003235659,0.0706276,0.678683,0.1519384,0.002341548,0.001674271,0.0007975145,0.00281697,0.01135055,0.06504813,0.0002688542],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.008632023,0.9735475,0.001029965,0.006687734,0.005721916,0.0008107287,0.0007955013,0.0000250434,0.002749599],"genre_scores_gemma":[0.2963743,0.6464737,0.01337502,0.0160153,0.02242255,0.002878314,0.001670346,0.00007314329,0.0007172088],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1254313,"threshold_uncertainty_score":0.6633523,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1777587551","doi":"10.1016/s0140-6736(15)00469-9","title":"Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":394,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Simon Fraser University; Université Laval; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Canadian Institutes of Health Research; International Development Research Centre; Heart and Stroke Foundation of Canada","keywords":"Pharmacy; Medicine; Environmental health; Disease; Middle income; Rural area; Socioeconomics; Business; Economics; Demographic economics; Family medicine","authors":[{"name":"Rasha Khatib","is_ca":true},{"name":"Martin McKee","is_ca":false},{"name":"Harry S. Shannon","is_ca":true},{"name":"Clara K Chow","is_ca":false},{"name":"Sumathy Rangarajan","is_ca":true},{"name":"Koon Teo","is_ca":true},{"name":"Wei Li","is_ca":false},{"name":"Prem Mony","is_ca":false},{"name":"Viswanathan Mohan","is_ca":false},{"name":"Rajeev Gupta","is_ca":false},{"name":"Rajesh Kumar","is_ca":false},{"name":"Krishnapillai Vijayakumar","is_ca":false},{"name":"Scott A. Lear","is_ca":true},{"name":"Rafael Díaz","is_ca":false},{"name":"Álvaro Avezum","is_ca":false},{"name":"Patricio López‐Jaramillo","is_ca":false},{"name":"Fernando Laņas","is_ca":false},{"name":"Khalid Yusoff","is_ca":false},{"name":"Noor Hassim Ismail","is_ca":false},{"name":"Khawar Kazmi","is_ca":false},{"name":"Omar Rahman","is_ca":false},{"name":"Annika Rosengren","is_ca":false},{"name":"Nahed Monsef","is_ca":false},{"name":"Roya Kelishadi","is_ca":false},{"name":"Annamarie Kruger","is_ca":false},{"name":"Thandi Puoane","is_ca":false},{"name":"Andrzej Szuba","is_ca":false},{"name":"Jephat Chifamba","is_ca":false},{"name":"Ahmet Temizhan","is_ca":false},{"name":"Gilles R. Dagenais","is_ca":true},{"name":"Amiram Gafni","is_ca":true},{"name":"Salim Yusuf","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08904064535655133,"gpt":0.2970635422064158,"spread":0.2080228968498645,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009039382,0.0007194226,0.002520562,0.002486435,0.0005186611,0.0022002,0.001948336,0.001500601,0.006073836],"category_scores_gemma":[0.02280677,0.001106878,0.007838693,0.006188736,0.001581463,0.001807151,0.002902159,0.002043328,0.0006660961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00070197,"about_ca_system_score_gemma":0.0009926495,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.05296877,"about_ca_topic_score_gemma":0.03708931,"domain_scores_codex":[0.9904448,0.006429344,0.000985851,0.0008242107,0.0004999856,0.0008157598],"domain_scores_gemma":[0.9456962,0.03465109,0.01254481,0.004009835,0.001497593,0.001600467],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002891523,0.0001702862,0.9730017,0.0004369136,0.0117445,0.0006207338,0.0003103208,0.00392115,0.0001872112,0.001140375,0.00213547,0.003439748],"study_design_scores_gemma":[0.00038739,0.0006051971,0.9837172,0.000127296,0.004295726,0.0004285942,0.001540725,0.005570081,0.000299032,0.0009341386,0.002017328,0.00007737307],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822156,0.004882426,0.0005718551,0.0006316216,0.00004212909,0.00003485062,0.01076644,0.00002621016,0.0008287926],"genre_scores_gemma":[0.9901407,0.001161523,0.0002845608,0.0001555106,0.00004450002,0.00003433694,0.007698738,0.00001551417,0.0004646321],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05296877,"threshold_uncertainty_score":0.1053209,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2770849724","doi":"10.3389/fonc.2017.00273","title":"Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":286,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Repurposing; Drug repositioning; Leverage (statistics); Clinical trial; Medicine; Cancer drugs; Drug development; Drug; Business; Approved drug; Alternative medicine; Government (linguistics); Pharmacology; Computer science; Engineering; Pathology","authors":[{"name":"J. Javier Hernández","is_ca":true},{"name":"Michael Pryszlak","is_ca":true},{"name":"Lindsay Smith","is_ca":true},{"name":"Connor Yanchus","is_ca":true},{"name":"Naheed Kurji","is_ca":false},{"name":"Vijay Shahani","is_ca":false},{"name":"Steven V. Molinski","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1036281468605397,"gpt":0.3817537428207261,"spread":0.2781255959601864,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003596422,0.0004985314,0.0008868534,0.0022751,0.0003843212,0.002454493,0.0007167452,0.002163803,0.004067574],"category_scores_gemma":[0.005286371,0.0002330254,0.0006044817,0.002963786,0.001888828,0.004261558,0.0008690174,0.003074431,0.0008774056],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001866727,"about_ca_system_score_gemma":0.002827158,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002157272,"about_ca_topic_score_gemma":0.003249121,"domain_scores_codex":[0.9987936,0.0005013805,0.00007521643,0.00009235109,0.0004542382,0.00008314488],"domain_scores_gemma":[0.9963716,0.002847995,0.0002863848,0.00009473285,0.0003272626,0.00007205644],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005572976,0.00008537032,0.000416548,0.008395214,0.0001003564,0.00029484,0.0002121926,0.00225375,0.0006086796,0.2962837,0.02620422,0.6650894],"study_design_scores_gemma":[0.00002585472,0.00007898745,0.001374824,0.009397886,0.00007054232,0.0008283005,0.0003501822,0.0006343165,0.0005135012,0.07488935,0.9117997,0.00003663801],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006698062,0.9826196,0.001404954,0.007959636,0.0003126557,0.000008802026,0.00001271053,0.000008021187,0.007003761],"genre_scores_gemma":[0.009546643,0.9849594,0.001255353,0.00204105,0.0007034747,0.00001547928,0.00001473332,0.000007446418,0.001456418],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004067574,"threshold_uncertainty_score":0.01901996,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2024556879","doi":"10.1086/467458","title":"Does Regulation Drive Out Competition in Pharmaceutical Markets?","year":2000,"lang":"en","type":"article","venue":"The Journal of Law and Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":242,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Competitor analysis; Competition (biology); Drug prices; Industrial organization; Business; Economics; Pharmacy; Public economics; Marketing","authors":[{"name":"Patricia M. Danzon","is_ca":false},{"name":"Li‐Wei Chao","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0416971653487621,"gpt":0.2816545989510505,"spread":0.2399574336022884,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01002179,0.0003297743,0.0015817,0.002075546,0.002256703,0.007041089,0.00102477,0.004190782,0.008773684],"category_scores_gemma":[0.03747291,0.0004787879,0.001876791,0.002911025,0.007678417,0.005701705,0.002759891,0.002981794,0.0008428579],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004673569,"about_ca_system_score_gemma":0.004219066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01645418,"about_ca_topic_score_gemma":0.01264442,"domain_scores_codex":[0.9842404,0.005649658,0.0008011335,0.002143997,0.003967213,0.003197604],"domain_scores_gemma":[0.9361556,0.034332,0.02255853,0.002157805,0.003296626,0.001499428],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000544963,0.0006870141,0.4586168,0.0008179529,0.0009426138,0.001214098,0.002735442,0.01036595,0.001607152,0.4449941,0.01277884,0.06469497],"study_design_scores_gemma":[0.00058455,0.0009886277,0.6348739,0.001032234,0.0007158157,0.0008898735,0.004234624,0.01482832,0.00227689,0.2483518,0.09097812,0.0002453126],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7745916,0.01075013,0.01040122,0.03822527,0.000261149,0.0002461083,0.0009119866,0.0001419091,0.1644706],"genre_scores_gemma":[0.991148,0.0009638758,0.0005018399,0.005806721,0.0002021887,0.00004187509,0.0001462104,0.00001229901,0.001176966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01645418,"threshold_uncertainty_score":0.05300093,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2077420003","doi":"10.1136/bmj.e4348","title":"Pharmaceutical research and development: what do we get for all that money?","year":2012,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":225,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"York University","funders":"","keywords":"Incentive; Mythology; Business; Economics; Market economy; Art; Literature","authors":[{"name":"Donald W. Light","is_ca":false},{"name":"Joel Lexchin","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.4040375696304965,"gpt":0.4486313239890954,"spread":0.04459375435859897,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03311346,0.001984851,0.003682165,0.005154525,0.007207355,0.0330186,0.003346649,0.02370664,0.0438837],"category_scores_gemma":[0.138404,0.0008256559,0.001781892,0.005452532,0.01867562,0.04553854,0.01144984,0.02148654,0.02226171],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.009912677,"about_ca_system_score_gemma":0.03027815,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009742506,"about_ca_topic_score_gemma":0.006772169,"domain_scores_codex":[0.9707686,0.01201453,0.001433434,0.001656487,0.01012829,0.003998534],"domain_scores_gemma":[0.8929502,0.04040319,0.008089612,0.00557046,0.02180834,0.0311782],"domain_codex":null,"domain_gemma":"evaluation","domain_candidate":"evaluation","domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002271781,0.000184284,0.001717757,0.001478447,0.0002727863,0.0001886894,0.0004612206,0.0003835231,0.0002052568,0.07998636,0.7737635,0.1411309],"study_design_scores_gemma":[0.0001492893,0.0001478411,0.002459837,0.003669103,0.0001380619,0.0003100573,0.002329712,0.0003835857,0.0002061396,0.1966105,0.7934479,0.0001480025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.0002421745,0.02414984,0.000426722,0.9642379,0.006502872,0.000007891489,0.00006586619,0.00005987773,0.004306851],"genre_scores_gemma":[0.04127023,0.09930683,0.003636908,0.8019368,0.03630545,0.0001164032,0.0002739067,0.0002970522,0.0168565],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.9668865,"threshold_uncertainty_score":0.1751229,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4210321301","doi":"","title":"Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe","year":2018,"lang":"en","type":"article","venue":"Archive ouverte UNIGE (University of Geneva)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":216,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Essential medicines; Economic shortage; Scopus; Antibiotic resistance; Business; Medicine; Antibiotics; Political science; Health care; MEDLINE; Biology; Law","authors":[{"name":"Mike Sharland","is_ca":false},{"name":"C. Pulcini","is_ca":false},{"name":"Stephan Harbarth","is_ca":false},{"name":"Mei Zeng","is_ca":false},{"name":"Sumanth Gandra","is_ca":false},{"name":"Shrey Mathur","is_ca":false},{"name":"Nicola Magrini","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07596587356098482,"gpt":0.2704283470410067,"spread":0.1944624734800218,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002303165,0.0005535117,0.0007951989,0.004388256,0.0005244503,0.001997533,0.0009417622,0.001031453,0.03168879],"category_scores_gemma":[0.03075654,0.0002444063,0.001275102,0.0041358,0.0003312442,0.002692196,0.001650007,0.001806903,0.0175671],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00127692,"about_ca_system_score_gemma":0.006270283,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01086311,"about_ca_topic_score_gemma":0.01910838,"domain_scores_codex":[0.9964162,0.0007230353,0.001090876,0.0001306595,0.001401797,0.0002374551],"domain_scores_gemma":[0.9912122,0.002318899,0.001867186,0.0003896951,0.003774855,0.0004371256],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002553162,0.00008635428,0.01489984,0.005212152,0.00007707026,0.0002005665,0.0003525189,0.0001634357,0.0004943259,0.003381412,0.6088173,0.3660597],"study_design_scores_gemma":[0.0001525178,0.000185283,0.03893603,0.01703946,0.0002152118,0.0007791695,0.001103781,0.0005384964,0.001342106,0.00569006,0.9339328,0.00008505955],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.03281669,0.1393753,0.0231015,0.2662492,0.01302084,0.00694861,0.1853328,0.002849358,0.3303055],"genre_scores_gemma":[0.2413226,0.2176994,0.2188965,0.09136017,0.008159245,0.005362058,0.1514931,0.001629527,0.06407732],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.03168879,"threshold_uncertainty_score":0.1060095,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2751849735","doi":"10.1016/s2468-2667(17)30141-x","title":"Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data","year":2017,"lang":"en","type":"article","venue":"The Lancet Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":214,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Hamilton Health Sciences; Université Laval; Simon Fraser University; Population Health Research Institute; McMaster University","funders":"Deanship of Scientific Research, King Saud University; Philippine Council for Health Research and Development; Canadian Institutes of Health Research; Servier; Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu; United Arab Emirates University; Universiti Kebangsaan Malaysia; Universiti Teknologi MARA; International Development Research Centre; Svenska Forskningsrådet Formas; Forskningsrådet för Arbetsliv och Socialvetenskap; Indian Council of Medical Research; North-West University; South Africa Netherlands research Programme on Alternatives in Development; Public Health Agency of Canada; AFA Försäkring; Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences; Universidad de La Frontera; Ministerstwo Edukacji i Nauki; GlaxoSmithKline; Vetenskapsrådet; Heart and Stroke Foundation of Canada; Boehringer Ingelheim; Ministry of Higher Education, Malaysia; AstraZeneca Canada; AstraZeneca","keywords":"Developing country; Medicine; Environmental health; Business; Economics; Economic growth","authors":[{"name":"Marjan Walli-Attaei","is_ca":true},{"name":"Rasha Khatib","is_ca":false},{"name":"Martin McKee","is_ca":false},{"name":"Scott A. Lear","is_ca":true},{"name":"Gilles R. Dagenais","is_ca":true},{"name":"Ehimario Igumbor","is_ca":false},{"name":"Khalid F. AlHabib","is_ca":true},{"name":"Manmeet Kaur","is_ca":false},{"name":"Iolanthé M. Kruger","is_ca":false},{"name":"Koon Teo","is_ca":true},{"name":"Fernando Laņas","is_ca":false},{"name":"Khalid Yusoff","is_ca":true},{"name":"Aytekin Oğuz","is_ca":false},{"name":"Rajeev Gupta","is_ca":false},{"name":"Afzalhussein Yusufali","is_ca":false},{"name":"Ahmad Bahonar","is_ca":false},{"name":"Raman Kutty","is_ca":false},{"name":"Annika Rosengren","is_ca":false},{"name":"Viswanathan Mohan","is_ca":false},{"name":"Álvaro Avezum","is_ca":false},{"name":"Rita Yusuf","is_ca":true},{"name":"Andrzej Szuba","is_ca":false},{"name":"Sumathy Rangarajan","is_ca":true},{"name":"Clara K Chow","is_ca":false},{"name":"Salim Yusuf","is_ca":true},{"name":"Martin O’Donnell","is_ca":true},{"name":"Andrew Mente","is_ca":false},{"name":"Darryl P. Leong","is_ca":false},{"name":"Andrew Smyth","is_ca":false},{"name":"Philip Joseph","is_ca":false},{"name":"Shofiqul Islam","is_ca":false},{"name":"M Zhang","is_ca":true},{"name":"Weiwei Hu","is_ca":false},{"name":"Chinthanie Ramasundarahettige","is_ca":false},{"name":"Gary Wong","is_ca":false},{"name":"Lovely Dayal","is_ca":true},{"name":"Amparo Casanova","is_ca":false},{"name":"Mahshid Dehghan","is_ca":true},{"name":"Gregory D. Lewis","is_ca":false},{"name":"Antonio Aliberti","is_ca":false},{"name":"Álvaro Reyes","is_ca":false},{"name":"Ahmed Zaki","is_ca":false},{"name":"Basil S. Lewis","is_ca":false},{"name":"B Zhang","is_ca":false},{"name":"D Agapay","is_ca":false},{"name":"Danielle M. Hari","is_ca":false},{"name":"E Milazzo","is_ca":false},{"name":"F Hussain","is_ca":true},{"name":"Fathimath Shifaly","is_ca":true},{"name":"Julija Rimac","is_ca":true},{"name":"John G. Swallow","is_ca":true},{"name":"L Heldman","is_ca":true},{"name":"Maha Mushtaha","is_ca":true},{"name":"Mark Trottier","is_ca":true},{"name":"N Aoucheva","is_ca":false},{"name":"N Kandy","is_ca":false},{"name":"Pam Mackie","is_ca":false},{"name":"Siu Lim Chin","is_ca":false},{"name":"S Ramacham","is_ca":false},{"name":"Sadequa Shahrook","is_ca":false},{"name":"T Tongana","is_ca":false},{"name":"W Elsheikh","is_ca":false},{"name":"J Lindeman","is_ca":true},{"name":"Matt J. McQueen","is_ca":true},{"name":"Kellie Hall","is_ca":false},{"name":"J. Keys","is_ca":true},{"name":"Xuechao Wang","is_ca":false},{"name":"J Keneth","is_ca":true},{"name":"Anitha Devanath","is_ca":false},{"name":"Rafael Díaz","is_ca":false},{"name":"Andrés Orlandini","is_ca":false},{"name":"B Linetsky","is_ca":false},{"name":"S Toscanelli","is_ca":false},{"name":"Germana Casaccia","is_ca":false},{"name":"JM Maini Cuneo","is_ca":false},{"name":"Omar Rahman","is_ca":false},{"name":"AK Azad","is_ca":false},{"name":"Khondkar Ayaz Rabbani","is_ca":false},{"name":"HM Cherry","is_ca":false},{"name":"Adnan Mannan","is_ca":false},{"name":"I Hassan","is_ca":false},{"name":"AT Talukdar","is_ca":false},{"name":"RB Tooheen","is_ca":false},{"name":"MU Khan","is_ca":false},{"name":"Mariz Sintaha","is_ca":true},{"name":"Tarzia Choudhury","is_ca":false},{"name":"Md Rabiul Haque","is_ca":false},{"name":"S Parvin","is_ca":false},{"name":"GB Oliveira","is_ca":false},{"name":"CS Marcílio","is_ca":false},{"name":"Antônio José Cordeiro Mattos","is_ca":false},{"name":"Jane DeJesus","is_ca":true},{"name":"Paul Poirier","is_ca":false},{"name":"Ginette Turbide","is_ca":false},{"name":"D. Auger","is_ca":false},{"name":"A LeBlanc De Bluts","is_ca":false},{"name":"MC Proulx","is_ca":false},{"name":"Marie‐Pierre Cayer","is_ca":true},{"name":"Nadine Bonneville","is_ca":false},{"name":"Danijela Gašević","is_ca":false},{"name":"E Corber","is_ca":false},{"name":"Veronica de Jong","is_ca":false},{"name":"I Vukmirovich","is_ca":false},{"name":"Andreas Wielgosz","is_ca":false},{"name":"George Fodor","is_ca":false},{"name":"Andrew Pipe","is_ca":false},{"name":"A Shane","is_ca":false},{"name":"Pamela Serón","is_ca":false},{"name":"S Martinez","is_ca":false},{"name":"A Valdebenito","is_ca":false},{"name":"María José Oliveros","is_ca":true},{"name":"Li Wei","is_ca":true},{"name":"Xingyu Wang","is_ca":false},{"name":"Wen­hua Zhao","is_ca":false},{"name":"Bo Hu","is_ca":false},{"name":"Yi Sun","is_ca":false},{"name":"Jian Bo","is_ca":false},{"name":"Zhao Xiuwen","is_ca":false},{"name":"Chang Xiaohong","is_ca":false},{"name":"Tao Chen","is_ca":false},{"name":"Hui Chen","is_ca":false},{"name":"Qing Deng","is_ca":false},{"name":"Xiaoru Cheng","is_ca":false},{"name":"He Xinye","is_ca":false},{"name":"Jian Li","is_ca":true},{"name":"Juan Li","is_ca":true},{"name":"Xu Liu","is_ca":false},{"name":"Ren Bing","is_ca":false},{"name":"Wang Wei","is_ca":false},{"name":"Yang Wang","is_ca":false},{"name":"Yi Zhai","is_ca":false},{"name":"Zhu Manlu","is_ca":false},{"name":"Fanghong Lu","is_ca":false},{"name":"Jianfang Wu","is_ca":false},{"name":"Yindong Li","is_ca":true},{"name":"Yan Hou","is_ca":false},{"name":"Liangqing Zhang","is_ca":false},{"name":"Baoxia Guo","is_ca":false},{"name":"Shiying Zhang","is_ca":false},{"name":"BianRongwen","is_ca":false},{"name":"TianXiuzhen","is_ca":false},{"name":"Dong Li","is_ca":true},{"name":"Di Chen","is_ca":false},{"name":"Wu Jianguo","is_ca":false},{"name":"Xiao Yize","is_ca":false},{"name":"Tianlu Liu","is_ca":false},{"name":"Peng Zhang","is_ca":false},{"name":"Changlin Dong","is_ca":false},{"name":"Xiaolan Ma","is_ca":true},{"name":"Yang Yuqing","is_ca":false},{"name":"Lei Rensheng","is_ca":false},{"name":"Fu Minfan","is_ca":false},{"name":"Jing He","is_ca":false},{"name":"Yü Liu","is_ca":true},{"name":"Xiaojie Xing","is_ca":false},{"name":"Zhou Qiang","is_ca":false},{"name":"Patricio López‐Jaramillo","is_ca":false},{"name":"Paul Anthony Camacho","is_ca":false},{"name":"R Garcia","is_ca":false},{"name":"LJA Jurado","is_ca":false},{"name":"Diego Gómez-Arbeláez","is_ca":false},{"name":"JF Arguello","is_ca":false},{"name":"R Dueñas","is_ca":false},{"name":"S Silva","is_ca":false},{"name":"LP Pradilla","is_ca":false},{"name":"F Ramírez","is_ca":true},{"name":"DI Molina","is_ca":false},{"name":"Carlos Cure-Cure","is_ca":false},{"name":"Suhey Pérez","is_ca":true},{"name":"E Hernandez","is_ca":false},{"name":"E. Arcos","is_ca":false},{"name":"S Fernandez","is_ca":false},{"name":"Claudia Narváez","is_ca":false},{"name":"J Paez","is_ca":true},{"name":"A Sotomayor","is_ca":false},{"name":"Henry García","is_ca":true},{"name":"G. Sánchez","is_ca":false},{"name":"T David","is_ca":false},{"name":"Prem Mony","is_ca":false},{"name":"Mário Vaz","is_ca":true},{"name":"A V Bharathi","is_ca":false},{"name":"Sumathi Swaminathan","is_ca":false},{"name":"Kiruba Shankar","is_ca":false},{"name":"AV Kurpad","is_ca":false},{"name":"KG Jayachitra","is_ca":false},{"name":"Narinder Kumar","is_ca":false},{"name":"Mohan Deepa","is_ca":false},{"name":"K Parthiban","is_ca":true},{"name":"M Anitha","is_ca":false},{"name":"S Hemavathy","is_ca":true},{"name":"T Rahulashankiruthiyayan","is_ca":false},{"name":"K Sridevi","is_ca":false},{"name":"RB Panwar","is_ca":false},{"name":"Indu Mohan","is_ca":false},{"name":"Priyanka Rastogi","is_ca":false},{"name":"S. Rastogi","is_ca":false},{"name":"R. Bhargava","is_ca":false},{"name":"Rajesh Kumar","is_ca":false},{"name":"JS Thakur","is_ca":false},{"name":"Binod Kumar Patro","is_ca":false},{"name":"P. V. M. Lakshmi","is_ca":false},{"name":"R Mahajan","is_ca":false},{"name":"P Chaudary","is_ca":false},{"name":"V. Raman Kutty","is_ca":false},{"name":"K. Vijayakumar","is_ca":false},{"name":"G Rajasree","is_ca":false},{"name":"AR Renjini","is_ca":false},{"name":"A Deepu","is_ca":false},{"name":"B. Sandhya","is_ca":false},{"name":"Stephen Asha","is_ca":false},{"name":"HS Soumya","is_ca":false},{"name":"Roya Kelishadi","is_ca":false},{"name":"Noushin Mohammadifard","is_ca":false},{"name":"Hadi Heidari","is_ca":false},{"name":"KK Ng","is_ca":false},{"name":"A Devi","is_ca":true},{"name":"NM Nasir","is_ca":false},{"name":"MM Yasin","is_ca":true},{"name":"Maizatullifah Miskan","is_ca":false},{"name":"EA Rahman","is_ca":true},{"name":"MKM Arsad","is_ca":true},{"name":"Farnaza Ariffin","is_ca":false},{"name":"SA Razak","is_ca":true},{"name":"FA Majid","is_ca":true},{"name":"NA Bakar","is_ca":false},{"name":"MY Yacob","is_ca":false},{"name":"N Zainon","is_ca":true},{"name":"Ruhaya Salleh","is_ca":false},{"name":"MKA Ramli","is_ca":false},{"name":"NA Halim","is_ca":false},{"name":"SR Norlizan","is_ca":false},{"name":"NM Ghazali","is_ca":false},{"name":"MN Arshad","is_ca":true},{"name":"R Razali","is_ca":false},{"name":"Syed Hassan Ali","is_ca":false},{"name":"HR Othman","is_ca":true},{"name":"CWJCW Hafar","is_ca":false},{"name":"A Pit","is_ca":false},{"name":"Norlaila Danuri","is_ca":false},{"name":"F Basir","is_ca":false},{"name":"SNA Zahari","is_ca":true},{"name":"Hafez Mohammad Ammar Abdullah","is_ca":false},{"name":"MA Arippin","is_ca":true},{"name":"NA Zakaria","is_ca":true},{"name":"MJ Hasni","is_ca":false},{"name":"MT Azmi","is_ca":false},{"name":"MI Zaleha","is_ca":false},{"name":"KY Hazdi","is_ca":false},{"name":"AR Rizam","is_ca":false},{"name":"W Sazman","is_ca":false},{"name":"A Azman","is_ca":false},{"name":"Umaiyeh Khammash","is_ca":false},{"name":"A Khatib","is_ca":false},{"name":"Rita Giacaman","is_ca":false},{"name":"Romania Iqbal","is_ca":false},{"name":"Asad Afridi","is_ca":false},{"name":"Rehman Khawaja","is_ca":false},{"name":"Auriba Raza","is_ca":false},{"name":"Khawar Kazmi","is_ca":false},{"name":"Antonio Dans","is_ca":false},{"name":"HU Co","is_ca":false},{"name":"JT Sanchez","is_ca":true},{"name":"L Pudol","is_ca":false},{"name":"C Zamora-Pudol","is_ca":true},{"name":"LAM Palileo-Villanueva","is_ca":false},{"name":"MR Aquino","is_ca":false},{"name":"C Abaquin","is_ca":false},{"name":"SL Pudol","is_ca":false},{"name":"ML Cabral","is_ca":false},{"name":"Witold Zatoński","is_ca":false},{"name":"Katarzyna Zatońska","is_ca":false},{"name":"Rafał Ilow","is_ca":false},{"name":"M Ferus","is_ca":false},{"name":"Bożena Regulska−Ilow","is_ca":true},{"name":"Dorota Różańska","is_ca":false},{"name":"Maria Wołyniec","is_ca":false},{"name":"Ahmad Hersi","is_ca":false},{"name":"Tarek Kashour","is_ca":false},{"name":"Hussam AlFaleh","is_ca":false},{"name":"Mostafa Q. Alshamiri","is_ca":true},{"name":"HB Altaradi","is_ca":true},{"name":"Omar Alnobani","is_ca":false},{"name":"A Bafart","is_ca":false},{"name":"Nour Alkamel","is_ca":false},{"name":"Mohammed K. Ali","is_ca":false},{"name":"Mahera Abdulrahman","is_ca":true},{"name":"Reza Nouri","is_ca":true},{"name":"A. Kruger","is_ca":false},{"name":"H H Voster","is_ca":false},{"name":"Aletta E. Schutte","is_ca":false},{"name":"Edelweiss Wentzel‐Viljoen","is_ca":false},{"name":"FC Eloff","is_ca":false},{"name":"H de Ridder","is_ca":false},{"name":"H Moss","is_ca":true},{"name":"J Potgieter","is_ca":true},{"name":"A.V. Diez Roux","is_ca":true},{"name":"Megan Watson","is_ca":false},{"name":"G de Wet","is_ca":true},{"name":"Antonel Olckers","is_ca":false},{"name":"Johann C. Jerling","is_ca":false},{"name":"Marlien Pieters","is_ca":false},{"name":"Trynke Hoekstra","is_ca":true},{"name":"Thandi Puoane","is_ca":false},{"name":"Lungiswa Tsolekile","is_ca":false},{"name":"David Sanders","is_ca":true},{"name":"Pooveshni Naidoo","is_ca":false},{"name":"N Steyn","is_ca":false},{"name":"Nasheeta Peer","is_ca":false},{"name":"Bongani M. Mayosi","is_ca":false},{"name":"Brian Rayner","is_ca":false},{"name":"Estelle V. Lambert","is_ca":false},{"name":"Naomi Levitt","is_ca":false},{"name":"Tracy Kolbe‐Alexander","is_ca":false},{"name":"Lucas Ntyintyane","is_ca":false},{"name":"G. Hughes","is_ca":true},{"name":"Rina Swart","is_ca":false},{"name":"Jean Fourie","is_ca":false},{"name":"Moïse Muzigaba","is_ca":true},{"name":"S Xapa","is_ca":true},{"name":"N Gobile","is_ca":false},{"name":"K Ndayi","is_ca":false},{"name":"B Jwili","is_ca":false},{"name":"K Ndibaza","is_ca":false},{"name":"Bonaventure Amandi Egbujie","is_ca":false},{"name":"Kristina Bengtsson Boström","is_ca":false},{"name":"U Lindblad","is_ca":false},{"name":"P Langkilde","is_ca":false},{"name":"A Gustavsson","is_ca":false},{"name":"Mattias Andréasson","is_ca":false},{"name":"M Snällman","is_ca":true},{"name":"L Wirdemann","is_ca":true},{"name":"Karen Odberg Pettersson","is_ca":true},{"name":"Erik Moberg","is_ca":false},{"name":"Karen Yeates","is_ca":false},{"name":"Jessica Sleeth","is_ca":false},{"name":"Kajiru Kilonzo","is_ca":true},{"name":"AAK Akalin","is_ca":false},{"name":"KBT Calik","is_ca":false},{"name":"Neşe İmeryüz","is_ca":false},{"name":"Ahmet Temizhan","is_ca":false},{"name":"Emel Alphan","is_ca":false},{"name":"Haydar Sur","is_ca":false},{"name":"Yüksel Altuntaş","is_ca":false},{"name":"AM Yusufali","is_ca":false},{"name":"Wael Almahmeed","is_ca":false},{"name":"H Swidan","is_ca":false},{"name":"EA Darwish","is_ca":true},{"name":"ARA Hashemi","is_ca":true},{"name":"Najib Al‐Khaja","is_ca":false},{"name":"J. Muscat-Baron","is_ca":false},{"name":"SH Ahmed","is_ca":false},{"name":"TM Mamdouh","is_ca":false},{"name":"WM Darwish","is_ca":false},{"name":"MHS Abdelmotagali","is_ca":false},{"name":"SA Omer Awed","is_ca":false},{"name":"GA Movahedi","is_ca":false},{"name":"H Al Shaibani","is_ca":true},{"name":"RIM Gharabou","is_ca":false},{"name":"DF Youssef","is_ca":false},{"name":"AZS Nawati","is_ca":false},{"name":"ZAR Abu Salah","is_ca":false},{"name":"RFE Abdalla","is_ca":false},{"name":"SM Al Shuwaihi","is_ca":false},{"name":"MA Al Omairi","is_ca":false},{"name":"OD Cadigal","is_ca":false},{"name":"R.S. Alejandrino","is_ca":false},{"name":"Jephat Chifamba","is_ca":false},{"name":"Lenon Gwaunza","is_ca":true},{"name":"G Terera","is_ca":true},{"name":"Carol Mahachi","is_ca":false},{"name":"Pretty Murambiwa","is_ca":false},{"name":"T Machiweni","is_ca":false},{"name":"RF Mapanga","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06005507458694665,"gpt":0.325043724570828,"spread":0.2649886499838813,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003448214,0.0005358165,0.001046781,0.002446764,0.0005296183,0.001046603,0.0008433215,0.0004308014,0.001659287],"category_scores_gemma":[0.00688338,0.0005535608,0.002501015,0.004678126,0.000677764,0.0008400024,0.002082409,0.0006115495,0.0001741489],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003918322,"about_ca_system_score_gemma":0.0004457066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01395781,"about_ca_topic_score_gemma":0.0147003,"domain_scores_codex":[0.9961413,0.002090465,0.0004983274,0.000499692,0.0004265309,0.0003438029],"domain_scores_gemma":[0.9889731,0.004033885,0.004720986,0.001085631,0.0006444661,0.000541993],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002185872,0.00003756963,0.997974,0.00005810203,0.0007243904,0.00007397,0.0001435191,0.0001147139,0.00004842473,0.00002603477,0.00007303825,0.0005077142],"study_design_scores_gemma":[0.00001351524,0.0001275527,0.9983938,0.00001811299,0.000199298,0.0001175871,0.0005871106,0.000383245,0.00002632285,0.0000174779,0.0001093387,0.000006573863],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985721,0.000246441,0.00007232441,0.0000152406,0.000001854879,0.00001177138,0.0009359898,0.000002040989,0.0001422228],"genre_scores_gemma":[0.998419,0.0001288824,0.0001334529,0.00001460022,0.000004421371,0.00002985637,0.00122694,0.000002193483,0.00004062093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01395781,"threshold_uncertainty_score":0.02775311,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2163707071","doi":"10.1377/hlthaff.w3.521","title":"Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries","year":2003,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":206,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Liberian dollar; Pound (networking); Economics; Agricultural economics; International economics; Demographic economics; Business; Finance","authors":[{"name":"Patricia M. Danzon","is_ca":false},{"name":"Michael F. Furukawa","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1186151573046771,"gpt":0.3518014459299277,"spread":0.2331862886252506,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001256827,0.0001615484,0.0003685185,0.002509961,0.0005235638,0.001962563,0.0003746574,0.0004694504,0.002125788],"category_scores_gemma":[0.008999592,0.0003090385,0.0005319988,0.006025532,0.0008622894,0.0009773746,0.00114738,0.0005694635,0.000223035],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000985996,"about_ca_system_score_gemma":0.0006265691,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03427188,"about_ca_topic_score_gemma":0.03370957,"domain_scores_codex":[0.9984459,0.0004100852,0.0002224376,0.0002601569,0.000449129,0.0002123071],"domain_scores_gemma":[0.9845354,0.004858007,0.007670464,0.0004566367,0.001788967,0.0006904705],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004735987,0.00005409463,0.9744013,0.0005210132,0.0006580197,0.0004809384,0.0005520211,0.0009618952,0.0001843011,0.001750205,0.002041401,0.01792123],"study_design_scores_gemma":[0.00005074008,0.0001026121,0.9906716,0.0002209582,0.0002022481,0.0004115118,0.001093461,0.0002236595,0.000332802,0.000260778,0.006406931,0.00002270416],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9655694,0.01702879,0.0002784473,0.001036028,0.00003729274,0.00001575428,0.004414086,0.00000844754,0.01161181],"genre_scores_gemma":[0.9917479,0.005731093,0.000131302,0.000142632,0.00002863335,0.000005852039,0.002006698,0.000004126221,0.0002018307],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03427188,"threshold_uncertainty_score":0.0681448,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2889089805","doi":"10.1016/s2213-8587(18)30233-x","title":"Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study","year":2018,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":200,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; Simon Fraser University; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; Population Health Research Institute","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Metformin; Pharmacy; Environmental health; Audit; Diabetes mellitus; Glibenclamide; Epidemiology; Family medicine; Business; Internal medicine; Accounting; Endocrinology","authors":[{"name":"Clara K Chow","is_ca":true},{"name":"Chinthanie Ramasundarahettige","is_ca":true},{"name":"Weihong Hu","is_ca":true},{"name":"Khalid F. AlHabib","is_ca":false},{"name":"Álvaro Avezum","is_ca":false},{"name":"Xiaoru Cheng","is_ca":false},{"name":"Jephat Chifamba","is_ca":false},{"name":"Gilles R. Dagenais","is_ca":true},{"name":"Antonio Dans","is_ca":false},{"name":"Bonaventure Amandi Egbujie","is_ca":false},{"name":"Rajeev Gupta","is_ca":false},{"name":"Romaina Iqbal","is_ca":false},{"name":"Noor Hassim Ismail","is_ca":false},{"name":"Miraç Vural Keskinler","is_ca":false},{"name":"Rasha Khatib","is_ca":false},{"name":"Iolanthé M. Kruger","is_ca":false},{"name":"Rajesh Kumar","is_ca":false},{"name":"Fernando Laņas","is_ca":false},{"name":"Scott A. Lear","is_ca":true},{"name":"Patricio López‐Jaramillo","is_ca":false},{"name":"Martin McKee","is_ca":false},{"name":"Noushin Mohammadifard","is_ca":false},{"name":"Viswanathan Mohan","is_ca":false},{"name":"Prem Mony","is_ca":false},{"name":"Andrés Orlandini","is_ca":false},{"name":"Annika Rosengren","is_ca":false},{"name":"Krishnapillai Vijayakumar","is_ca":false},{"name":"Wei Li","is_ca":false},{"name":"Karen Yeates","is_ca":true},{"name":"Khalid Yusoff","is_ca":false},{"name":"Rita Yusuf","is_ca":false},{"name":"Afzalhussein Yusufali","is_ca":false},{"name":"Katarzyna Zatońska","is_ca":false},{"name":"Yihong Zhou","is_ca":false},{"name":"Daniel J. Corsi","is_ca":true},{"name":"Sumathy Rangarajan","is_ca":true},{"name":"Koon Teo","is_ca":true},{"name":"Hertzel C. Gerstein","is_ca":true},{"name":"Salim Yusuf","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04565561249153537,"gpt":0.3240000573649068,"spread":0.2783444448733714,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001609716,0.0003639228,0.0006267318,0.001549313,0.0005687125,0.001496406,0.0007442542,0.001015193,0.002666493],"category_scores_gemma":[0.004528997,0.0007916564,0.001920494,0.004860878,0.00081853,0.001447702,0.001755371,0.001662471,0.0003086086],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005695644,"about_ca_system_score_gemma":0.0004305126,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02665556,"about_ca_topic_score_gemma":0.02051129,"domain_scores_codex":[0.9985039,0.0004593879,0.0002709536,0.000282115,0.0001438925,0.0003397223],"domain_scores_gemma":[0.9931282,0.00133106,0.003797727,0.0005482495,0.0004545304,0.0007403472],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001450452,0.00005397701,0.9985179,0.00002415208,0.0002885955,0.00005766728,0.0001158263,0.0000848191,0.00003559221,0.00008821776,0.0001440097,0.0004441989],"study_design_scores_gemma":[0.000009962965,0.0000544952,0.9987869,0.00002143958,0.0001112107,0.00009840993,0.000506399,0.0001412241,0.0000179697,0.000065819,0.0001780102,0.000008151528],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963291,0.001220303,0.0000870373,0.0001648128,0.00001155397,0.000006651311,0.001762588,0.000002408173,0.0004156408],"genre_scores_gemma":[0.9987916,0.000330454,0.00005418343,0.00003412021,0.000007765309,0.00000508728,0.000697631,0.000001661048,0.00007750723],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02665556,"threshold_uncertainty_score":0.05300081,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1969868159","doi":"10.2190/4m3e-l0yf-w1td-ekg0","title":"Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence","year":2004,"lang":"en","type":"review","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":199,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"York University","funders":"","keywords":"Cost sharing; Medical prescription; Prescription drug; Subsidy; Drug; Health care; Prescription costs; Business; Medicine; Public economics; Environmental health; Actuarial science; Economic growth; Economics; Pharmacology; Nursing","authors":[{"name":"Joel Lexchin","is_ca":true},{"name":"Paul Grootendorst","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1131953707533533,"gpt":0.4064047241796713,"spread":0.293209353426318,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006684667,0.0007589589,0.005050266,0.00611821,0.0002498061,0.001382266,0.0008545981,0.001034113,0.002916335],"category_scores_gemma":[0.03278666,0.0006049639,0.004241692,0.009149154,0.0005071732,0.001028577,0.0008261356,0.0006388391,0.0002104245],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001889255,"about_ca_system_score_gemma":0.004758597,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008730368,"about_ca_topic_score_gemma":0.025569,"domain_scores_codex":[0.9954746,0.001801557,0.001079904,0.0003277498,0.001213327,0.0001028426],"domain_scores_gemma":[0.968468,0.02414502,0.004822396,0.0002967519,0.002012324,0.0002556152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0006820363,0.00004407119,0.005978027,0.7155476,0.02323007,0.0002230902,0.0001395915,0.0003816362,0.0001510535,0.0004854774,0.004588027,0.2485494],"study_design_scores_gemma":[0.0008215315,0.0007030222,0.06610589,0.6428054,0.2118737,0.001818317,0.0004420865,0.0004180295,0.0005719366,0.001515628,0.07283013,0.0000943304],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008479605,0.9985483,0.00004679748,0.0001266424,0.0000265809,0.00003041815,0.000187957,0.000002108757,0.0001830657],"genre_scores_gemma":[0.01033784,0.9891962,0.0001740488,0.0001033737,0.00002489091,0.000035064,0.00008037766,0.000001182521,0.00004702372],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008730368,"threshold_uncertainty_score":0.03535229,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2147450289","doi":"10.1345/aph.1p389","title":"Physician Perceptions About Generic Drugs","year":2011,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":193,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Family medicine; Descriptive statistics; Likert scale; Generic drug; Logistic regression; Perception; Population; Quarter (Canadian coin); Health care; Environmental health; Drug; Internal medicine; Pharmacology; Psychology","authors":[{"name":"William H. Shrank","is_ca":false},{"name":"Joshua N. Liberman","is_ca":false},{"name":"Michael A. Fischer","is_ca":false},{"name":"Charmaine Girdish","is_ca":false},{"name":"Troyen A. Brennan","is_ca":false},{"name":"Niteesh K. Choudhry","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2192757037191003,"gpt":0.3669874518227134,"spread":0.147711748103613,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003288113,0.0001262215,0.0002217263,0.0004208441,0.0003800189,0.0009039862,0.00018653,0.0005392984,0.006061994],"category_scores_gemma":[0.01629647,0.0001065896,0.0003883638,0.0002973242,0.0005379874,0.0004628799,0.0004725354,0.0006528604,0.0003935486],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005731521,"about_ca_system_score_gemma":0.0005921583,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002968435,"about_ca_topic_score_gemma":0.002204634,"domain_scores_codex":[0.9972767,0.001132124,0.0002293899,0.0001487452,0.001018666,0.0001942995],"domain_scores_gemma":[0.9844855,0.006370285,0.005720796,0.0002486954,0.001495092,0.001679704],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"qualitative","study_design_scores_codex":[0.0005946652,0.0002581004,0.9155671,0.0007030665,0.0001983285,0.0007744441,0.01431797,0.0004099961,0.003371047,0.0006327384,0.004324098,0.0588485],"study_design_scores_gemma":[0.00006569737,0.001289366,0.9680127,0.00033811,0.0001139778,0.002543346,0.01431345,0.0004020037,0.0005860091,0.0004308324,0.01186618,0.00003836551],"study_design_candidate":"qualitative","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796371,0.002871956,0.000523284,0.004019091,0.00006152961,0.00003879514,0.0002268649,0.00001236962,0.01260895],"genre_scores_gemma":[0.9977764,0.000909479,0.0001789495,0.0007090305,0.00004990654,0.000005957036,0.00005501559,0.000001628231,0.0003135852],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006061994,"threshold_uncertainty_score":0.02027941,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1950143140","doi":"","title":"Encouraging the use of generic medicines: implications for transition economies.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":190,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Competition (biology); Business; Payment; Generic drug; Promotion (chess); Public economics; Marketing; Market share; Demand side; Quality (philosophy); Industrial organization; Economics; Finance; Drug; Microeconomics; Medicine","authors":[{"name":"Derek King","is_ca":false},{"name":"Panos Kanavos","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2495848310577156,"gpt":0.2688195064364776,"spread":0.019234675378762,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001800269,0.0003967782,0.0003648493,0.001494432,0.0009198372,0.002869842,0.0004308776,0.002687315,0.009035466],"category_scores_gemma":[0.006852862,0.0001029754,0.0005491205,0.002398465,0.001486044,0.004743739,0.001498677,0.001558418,0.0003757503],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00414684,"about_ca_system_score_gemma":0.004379626,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01369475,"about_ca_topic_score_gemma":0.01669236,"domain_scores_codex":[0.9994541,0.000237176,0.00003654015,0.0000352755,0.00008412056,0.0001527457],"domain_scores_gemma":[0.9948153,0.003329147,0.0008044684,0.00004706116,0.0004250744,0.0005789527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005736372,0.0002806198,0.02092418,0.004736517,0.0001379644,0.003178989,0.001412854,0.01272175,0.0004555094,0.5482635,0.07386754,0.3334469],"study_design_scores_gemma":[0.0002333907,0.0007320197,0.0816052,0.0078814,0.0004064355,0.003655744,0.02152484,0.007086293,0.001001862,0.5033652,0.3723312,0.0001764267],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.0450138,0.324013,0.004519687,0.5879076,0.001584571,0.0001605005,0.0006451337,0.00005727938,0.03609852],"genre_scores_gemma":[0.5839239,0.3644056,0.003936108,0.0373997,0.001991784,0.0001390075,0.0003229604,0.000009699133,0.007871308],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01369475,"threshold_uncertainty_score":0.03022665,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2045394072","doi":"10.1056/nejmsa003087","title":"Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors","year":2002,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":181,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Ministry of Health","funders":"Ministry of Health, British Columbia; Pfizer; Bristol-Myers Squibb; Deutsche Forschungsgemeinschaft; Agency for Healthcare Research and Quality; U.S. Department of Health and Human Services","keywords":"Medicine; Medical prescription; Cost sharing; Angiotensin-converting enzyme; Confidence interval; Christian ministry; Hazard ratio; Emergency medicine; Internal medicine; Pharmacology; Blood pressure","authors":[{"name":"Sebastian Schneeweiß","is_ca":false},{"name":"Alexander M. Walker","is_ca":false},{"name":"Robert J. Glynn","is_ca":false},{"name":"Malcolm Maclure","is_ca":true},{"name":"Colin R. Dormuth","is_ca":true},{"name":"Stephen B. Soumerai","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1048040640905049,"gpt":0.2984694581268024,"spread":0.1936653940362975,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007891279,0.0002954006,0.0006788094,0.0009328058,0.0006363952,0.001880311,0.0008559846,0.00101347,0.002132335],"category_scores_gemma":[0.05380757,0.000216793,0.001561488,0.00192293,0.0006918616,0.000932286,0.001005136,0.002240532,0.0001717495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00295727,"about_ca_system_score_gemma":0.001944377,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04297468,"about_ca_topic_score_gemma":0.01867466,"domain_scores_codex":[0.9923264,0.003343099,0.0005954559,0.0007203732,0.001862211,0.001152478],"domain_scores_gemma":[0.9399152,0.02058612,0.02870444,0.002924088,0.004929048,0.002941134],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001828365,0.0002065536,0.986828,0.00005189402,0.0004442384,0.0002062534,0.00007066908,0.0008831272,0.00004960274,0.0002861691,0.001012844,0.008132244],"study_design_scores_gemma":[0.0000719283,0.000436309,0.9959816,0.00003746603,0.0002082632,0.0003259008,0.0001014322,0.001862336,0.00009084726,0.0003165403,0.0005497811,0.00001761009],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943403,0.002039736,0.0001962467,0.0005864227,0.00004480551,0.00002615417,0.001223029,0.00001107359,0.001532191],"genre_scores_gemma":[0.9988,0.0001355446,0.00005701154,0.00006459157,0.00002416565,0.000005883701,0.0007899737,0.000002160751,0.0001205656],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04297468,"threshold_uncertainty_score":0.0854491,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135643683","doi":"10.1093/heapol/czh021","title":"Interactions between patent medicine vendors and customers in urban and rural Nigeria","year":2004,"lang":"en","type":"article","venue":"Health Policy and Planning","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":179,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Rockefeller Foundation; United States Agency for International Development","keywords":"Medical prescription; Quarter (Canadian coin); Business; Payment; Medicine; Position (finance); Marketing; Family medicine; Advertising; Nursing; History","authors":[{"name":"William R. Brieger","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1544873155491275,"gpt":0.3877181498090497,"spread":0.2332308342599221,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006470038,0.0002277224,0.0004110987,0.0005828773,0.003065848,0.001364223,0.0004438154,0.0009644791,0.002773524],"category_scores_gemma":[0.001879994,0.0005747021,0.00020103,0.0006278172,0.0007972562,0.00104808,0.001248475,0.0009391095,0.0003787708],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007617003,"about_ca_system_score_gemma":0.0007088285,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006983549,"about_ca_topic_score_gemma":0.01392474,"domain_scores_codex":[0.9992213,0.0003681934,0.00004754874,0.00006334329,0.0001221032,0.0001774569],"domain_scores_gemma":[0.9984458,0.0005649873,0.0005559373,0.00003462766,0.0001347009,0.0002638662],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003075724,0.0006106467,0.7787715,0.0001365127,0.00002561663,0.00398077,0.1983248,0.00007621915,0.001831753,0.0002491172,0.0008644817,0.01482109],"study_design_scores_gemma":[0.00001130644,0.0006889418,0.4759487,0.00007343538,0.00002197224,0.002125895,0.5180211,0.0003414937,0.0003641479,0.00009413252,0.00227115,0.00003773721],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9996011,0.00005259831,0.00001478349,0.000055431,0.000001428704,0.000006256837,0.000010488,5.927801e-7,0.0002573648],"genre_scores_gemma":[0.9991012,0.0001944004,0.00008344156,0.00009399676,0.000005246109,0.00001135854,0.00001824829,0.000001189801,0.0004909851],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006983549,"threshold_uncertainty_score":0.0138858,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2082501248","doi":"10.1111/j.1528-1167.2007.01007.x","title":"Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes","year":2007,"lang":"en","type":"article","venue":"Epilepsia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":178,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Group for Research in Decision Analysis; McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Lamotrigine; Clobazam; Pharmacy; Epilepsy; Adverse effect; Drug; Anticonvulsant; Generic drug; Brand names; Pharmacology; Family medicine; Psychiatry; Advertising","authors":[{"name":"Frédérick Andermann","is_ca":true},{"name":"Mei Sheng Duh","is_ca":false},{"name":"Antoine Gosselin","is_ca":true},{"name":"Pierre Emmanuel Paradis","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03838946776967719,"gpt":0.2809520929485794,"spread":0.2425626251789022,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001205244,0.0001946238,0.0003075061,0.0009627857,0.0002914198,0.0006661885,0.000501336,0.0003713624,0.001355424],"category_scores_gemma":[0.00439999,0.0001661047,0.0005415241,0.001991671,0.0003558355,0.0003633136,0.0003743325,0.00045658,0.0001103864],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002478895,"about_ca_system_score_gemma":0.001004874,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.07534926,"about_ca_topic_score_gemma":0.09429579,"domain_scores_codex":[0.9982151,0.0002863723,0.0002687157,0.0002960542,0.0007555216,0.0001783523],"domain_scores_gemma":[0.9942204,0.0009427664,0.003969615,0.0002424917,0.0003713461,0.0002535027],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001800654,0.00002381933,0.9939435,0.00002191063,0.00007325238,0.0000679453,0.00007765852,0.00005733815,0.0002130135,0.00001550175,0.00009142927,0.005234567],"study_design_scores_gemma":[0.00001021831,0.00003904516,0.9991933,0.000005354784,0.00003050466,0.0002339153,0.00005387426,0.0002158741,0.0001070512,0.00000800551,0.000100774,0.000002085679],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985782,0.0004986889,0.0000866232,0.0000905563,0.000002320362,0.00001258323,0.0003558559,0.000005637009,0.0003696136],"genre_scores_gemma":[0.9991211,0.0001922804,0.0001034198,0.00006096871,0.000006746321,0.000004512271,0.0004385103,0.000001635259,0.00007070518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07534926,"threshold_uncertainty_score":0.1498214,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3200608261","doi":"10.1016/s1470-2045(21)00463-0","title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":171,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Queen's University; World Health Organization","keywords":"Medicine; Snowball sampling; Essential medicines; Access to medicines; Cross-sectional study; Family medicine; Developing country; Descriptive statistics; Public health; Alternative medicine; Global health; Cancer; Environmental health; Nursing; Economic growth; Pathology","authors":[{"name":"Adam Fundytus","is_ca":true},{"name":"Manju Sengar","is_ca":false},{"name":"Dorothy Lombe","is_ca":false},{"name":"Wilma M. Hopman","is_ca":true},{"name":"Matthew Jalink","is_ca":true},{"name":"Bishal Gyawali","is_ca":true},{"name":"Dario Trapani","is_ca":false},{"name":"Felipe Roitberg","is_ca":false},{"name":"Elisabeth G.E. de Vries","is_ca":false},{"name":"Lorenzo Moja","is_ca":false},{"name":"André Ilbawi","is_ca":false},{"name":"Richard Sullivan","is_ca":false},{"name":"Christopher M. Booth","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2309375012748338,"gpt":0.4812587039765077,"spread":0.2503212027016739,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002534082,0.0002720861,0.0004166653,0.00131602,0.0005048997,0.0008301103,0.0003985184,0.0007349696,0.002153544],"category_scores_gemma":[0.00460784,0.0005678001,0.0003958853,0.002710518,0.0004684424,0.001180089,0.00105503,0.0007596478,0.0005599137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004835577,"about_ca_system_score_gemma":0.000551632,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01008123,"about_ca_topic_score_gemma":0.009394783,"domain_scores_codex":[0.9984738,0.0005421697,0.0002751038,0.0002328732,0.0002103545,0.0002656973],"domain_scores_gemma":[0.9954441,0.001017288,0.00220625,0.0002446991,0.0004366944,0.0006510707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00005251542,0.00009878442,0.9962788,0.00004982716,0.00002554289,0.00007120246,0.001198221,0.00004182018,0.0001449213,0.00001787153,0.0004480031,0.001572485],"study_design_scores_gemma":[0.000009480385,0.0001534991,0.9957373,0.00003409958,0.00001413924,0.0001390664,0.003212491,0.00009499017,0.00005363372,0.000006492136,0.0005392433,0.000005516145],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962347,0.0001866394,0.00008761339,0.0001118295,0.000003945572,0.00008190395,0.002169906,0.000005161803,0.001118402],"genre_scores_gemma":[0.9976737,0.0003175878,0.0002109033,0.0002498091,0.000006262623,0.0001014701,0.001256883,0.000003299283,0.0001800417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01008123,"threshold_uncertainty_score":0.0200451,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2127520342","doi":"10.1016/s0140-6736(02)11527-3","title":"The pharmaceutical industry as a medicines provider","year":2002,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":167,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Business; Intellectual property; Developing country; Drug prices; Essential drugs; Production (economics); Pharmaceutical industry; Essential medicines; International trade; Developed country; Access to medicines; Marginal cost; Industrial organization; Public economics; Commerce; Health care; Economic growth; Economics; Environmental health; Medicine; Health services; Pharmacology","authors":[{"name":"David Henry","is_ca":false},{"name":"Joel Lexchin","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2876269035881042,"gpt":0.4138744655755267,"spread":0.1262475619874224,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003673568,0.001048067,0.001751573,0.003032666,0.0005582234,0.003265422,0.0009892201,0.00574459,0.006288591],"category_scores_gemma":[0.008263137,0.0004453229,0.0005199827,0.007103488,0.001952072,0.003463532,0.0008757806,0.004124474,0.002163721],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004269252,"about_ca_system_score_gemma":0.008596033,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006457775,"about_ca_topic_score_gemma":0.01679318,"domain_scores_codex":[0.998382,0.0006128447,0.0001102041,0.0001442174,0.0006534663,0.00009717856],"domain_scores_gemma":[0.9924673,0.005135281,0.001001573,0.0001111785,0.0009884136,0.0002961948],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001598872,0.00007633572,0.0003704789,0.01848948,0.0001733787,0.0001883883,0.00005932769,0.0008793216,0.0002666335,0.04255979,0.2267126,0.7100644],"study_design_scores_gemma":[0.00008145844,0.00004497357,0.001422559,0.01009726,0.0001723584,0.0004359811,0.00009587721,0.0001932052,0.0001386703,0.01928483,0.9680159,0.00001682814],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003637536,0.9913496,0.00007795562,0.006302852,0.0006290008,0.00000256972,0.00001237527,0.000003038648,0.001586251],"genre_scores_gemma":[0.0009038686,0.9951768,0.0001365871,0.002053896,0.00102739,0.000004568453,0.000009518741,0.000001356779,0.0006860382],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006457775,"threshold_uncertainty_score":0.03097576,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2111436115","doi":"10.1111/j.1468-2354.2010.00615.x","title":"A DYNAMIC OLIGOPOLY STRUCTURAL MODEL FOR THE PRESCRIPTION DRUG MARKET AFTER PATENT EXPIRATION*","year":2010,"lang":"en","type":"article","venue":"International Economic Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":166,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Oligopoly; Expiration date; Welfare; Nested logit; Microeconomics; Expiration; Economics; Prescription drug; Consumer welfare; Medical prescription; Market structure; Business; Industrial organization; Econometrics; Medicine; Market economy; Pharmacology","authors":[{"name":"Andrew T. Ching","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06074069930950473,"gpt":0.3125100873626672,"spread":0.2517693880531625,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002209016,0.00142562,0.003202005,0.001238291,0.001519137,0.004105493,0.003448358,0.004737484,0.02637274],"category_scores_gemma":[0.004255108,0.001286807,0.001900083,0.002128721,0.002763253,0.003947693,0.001915664,0.003865768,0.003247133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004984215,"about_ca_system_score_gemma":0.003927098,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02455602,"about_ca_topic_score_gemma":0.02317981,"domain_scores_codex":[0.9983287,0.0006023765,0.00005633471,0.0003899438,0.000200866,0.0004217573],"domain_scores_gemma":[0.9970562,0.001623783,0.0005636868,0.0001364382,0.0002517014,0.0003680819],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.0001841683,0.0001802789,0.001000822,0.0001499827,0.00008249676,0.0004616957,0.0001437463,0.5263786,0.0008673099,0.4586501,0.005127308,0.00677351],"study_design_scores_gemma":[0.0003192518,0.0001643791,0.0006649221,0.00003674124,0.00006369961,0.0001282892,0.00009927157,0.8249313,0.0001192643,0.1663056,0.007095235,0.00007209045],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"methods","genre_gemma":"empirical","genre_scores_codex":[0.1127818,0.002458135,0.7597147,0.01085752,0.0004971777,0.0007354924,0.005535102,0.0007210171,0.1066991],"genre_scores_gemma":[0.8414968,0.003048696,0.05054145,0.0009463629,0.0003412524,0.0008658236,0.001404739,0.0001325244,0.1012223],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02637274,"threshold_uncertainty_score":0.0882256,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2105192804","doi":"10.1038/nchembio.1113","title":"A public-private partnership to unlock the untargeted kinome","year":2012,"lang":"en","type":"article","venue":"Nature Chemical Biology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":151,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Structural Genomics Consortium","funders":"Engineering and Physical Sciences Research Council; Cancer Research UK; Wellcome Trust","keywords":"Kinome; General partnership; Drug discovery; Business; Redundancy (engineering); Access to medicines; Kinase; Intellectual property; Computational biology; Computer science; Data science; Chemistry; Biology; Bioinformatics; Biochemistry; Finance","authors":[{"name":"Stefan Knapp","is_ca":false},{"name":"Paulo Arruda","is_ca":false},{"name":"Julian Blagg","is_ca":false},{"name":"S.K. Burley","is_ca":false},{"name":"David H. Drewry","is_ca":false},{"name":"A.M. Edwards","is_ca":true},{"name":"Doriano Fabbro","is_ca":false},{"name":"Paul Gillespie","is_ca":false},{"name":"Nathanael S. Gray","is_ca":false},{"name":"Bernhard Küster","is_ca":false},{"name":"Karen Lackey","is_ca":false},{"name":"Paulo Mazzafera","is_ca":false},{"name":"Nicholas C. O. Tomkinson","is_ca":false},{"name":"Timothy M. Willson","is_ca":false},{"name":"Paul Workman","is_ca":false},{"name":"William J. Zuercher","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1039065332046124,"gpt":0.3186126969108578,"spread":0.2147061637062454,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01857987,0.0004619996,0.0008332704,0.001117118,0.00250006,0.007677222,0.001727845,0.00816555,0.02731623],"category_scores_gemma":[0.03964998,0.0004757232,0.000579746,0.001332066,0.005602564,0.01595538,0.01188168,0.008318669,0.003709087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00345099,"about_ca_system_score_gemma":0.01471434,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001532519,"about_ca_topic_score_gemma":0.00171506,"domain_scores_codex":[0.9931166,0.003265839,0.0001507308,0.0007795473,0.001609165,0.001078115],"domain_scores_gemma":[0.9508842,0.02376028,0.002130478,0.009019925,0.004543746,0.009661397],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002164421,0.0003225738,0.001451512,0.0001216236,0.00006691802,0.0002368383,0.0006383033,0.004281002,0.001903011,0.8720394,0.0424145,0.07630795],"study_design_scores_gemma":[0.00008571637,0.00006385086,0.0007437689,0.00009087708,0.00001486771,0.000102793,0.000421169,0.0085606,0.0006811259,0.8931831,0.09601596,0.00003616289],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.05275185,0.005313957,0.2636296,0.4947099,0.003564114,0.0003063767,0.0005996685,0.001119969,0.1780046],"genre_scores_gemma":[0.909573,0.002253892,0.03000747,0.02602505,0.001325898,0.0003036134,0.0002306472,0.0002534258,0.03002712],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.02731623,"threshold_uncertainty_score":0.09826094,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1989028508","doi":"10.1503/cmaj.1041606","title":"Rofecoxib (Vioxx) voluntarily withdrawn from market","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":143,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false},"ca_institutions":"","funders":"","keywords":"Medicine; Sepsis; SOFA score; Internal medicine; Pediatrics; Emergency medicine","authors":[{"name":"B. Sibbald","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01529079297004724,"gpt":0.2289253502067974,"spread":0.2136345572367501,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008424171,0.0002052224,0.0004385229,0.0003248128,0.0004478127,0.0008142712,0.0002614078,0.0004776307,0.02110962],"category_scores_gemma":[0.002121352,0.0001362214,0.0004734405,0.0005662676,0.0002475959,0.0003609983,0.000256109,0.0005861812,0.00364128],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006198853,"about_ca_system_score_gemma":0.001280353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002181477,"about_ca_topic_score_gemma":0.003095209,"domain_scores_codex":[0.9994643,0.0001385474,0.00008791703,0.00006987906,0.0001488303,0.00009045031],"domain_scores_gemma":[0.9983228,0.0002812732,0.0007553402,0.0001418892,0.0002560104,0.000242654],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03174939,0.00211751,0.3057304,0.003626251,0.0009790715,0.003675482,0.0004101331,0.0003150234,0.01761816,0.002064975,0.1214355,0.5102781],"study_design_scores_gemma":[0.005869466,0.01043378,0.5643082,0.0009591477,0.0005725344,0.004694856,0.0005358225,0.001138435,0.01016621,0.0005419569,0.4007114,0.00006813577],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"editorial","genre_scores_codex":[0.8343369,0.02956224,0.001855379,0.007086782,0.00188583,0.002329174,0.03320653,0.0003934659,0.0893437],"genre_scores_gemma":[0.9385016,0.004290585,0.0009819276,0.003602124,0.001113378,0.0007585158,0.01004642,0.00005442887,0.04065089],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.02110962,"threshold_uncertainty_score":0.07061869,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015351537","doi":"10.1016/j.seizure.2005.12.010","title":"Are there potential problems with generic substitution of antiepileptic drugs?","year":2006,"lang":"en","type":"review","venue":"Seizure","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":143,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Dosing; Intensive care medicine; Adverse effect; Bioequivalence; Drug; Epilepsy; Risk analysis (engineering); Psychiatry; Pharmacology; Pharmacokinetics","authors":[{"name":"Pamela Crawford","is_ca":false},{"name":"M. Feely","is_ca":false},{"name":"A. Guberman","is_ca":true},{"name":"Günter Krämer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07921406813877387,"gpt":0.2875214318073167,"spread":0.2083073636685429,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004815055,0.0004235794,0.001794753,0.00147537,0.0002133753,0.001592826,0.00124069,0.00223879,0.008310817],"category_scores_gemma":[0.007862648,0.0002576841,0.0009815169,0.003408251,0.001425683,0.00286407,0.0006540982,0.001924914,0.001243181],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001260741,"about_ca_system_score_gemma":0.002164021,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002099451,"about_ca_topic_score_gemma":0.005403206,"domain_scores_codex":[0.9988624,0.0004588872,0.000137515,0.0001190143,0.0003337386,0.00008839829],"domain_scores_gemma":[0.9923815,0.005256259,0.001380503,0.0001744589,0.0007034001,0.0001039295],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002613599,0.00008507541,0.002204931,0.01004299,0.0003252645,0.0003682929,0.00007720775,0.001746935,0.0004823685,0.03586384,0.02381583,0.9247259],"study_design_scores_gemma":[0.0003887937,0.0003907701,0.01473863,0.0153028,0.000814341,0.006037664,0.0005896079,0.001837729,0.0008737195,0.07919741,0.8797635,0.00006492923],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002086697,0.967339,0.001513013,0.02209954,0.0003697707,0.00001027905,0.0001189346,0.00001436562,0.006448406],"genre_scores_gemma":[0.02244235,0.9670544,0.001905013,0.006028294,0.001350446,0.0000166801,0.00009538336,0.00001047305,0.001096885],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008310817,"threshold_uncertainty_score":0.02780247,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2999258267","doi":"10.1136/bmj.l4627","title":"Pricing of pharmaceuticals is becoming a major challenge for health systems","year":2020,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":141,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"World Health Organization","keywords":"Drug pricing; Business; Market power; Healthcare system; Industrial organization; Risk analysis (engineering); Economics; Computer science; Health care; Marketing; Microeconomics; Actuarial science; Economic growth","authors":[{"name":"Steven G. Morgan","is_ca":true},{"name":"Hannah S Bathula","is_ca":false},{"name":"Suerie Moon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2604861698715185,"gpt":0.4106091592542288,"spread":0.1501229893827103,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02851525,0.0008770043,0.001330119,0.001803559,0.004959477,0.01942176,0.002407621,0.02867102,0.01766034],"category_scores_gemma":[0.1270678,0.0007308749,0.001654219,0.001905088,0.01015535,0.01630115,0.004908341,0.02811839,0.006545339],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01033401,"about_ca_system_score_gemma":0.02466818,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009444811,"about_ca_topic_score_gemma":0.01346897,"domain_scores_codex":[0.9593154,0.01166838,0.001644722,0.001927965,0.02294744,0.002496089],"domain_scores_gemma":[0.8492751,0.08860494,0.008488078,0.006109729,0.03182331,0.01569874],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004491439,0.00008968639,0.0007575662,0.0001958096,0.00008141668,0.0001031884,0.0003683392,0.0006428308,0.0002508442,0.1284304,0.8248206,0.0442144],"study_design_scores_gemma":[0.00008520886,0.00009306165,0.001291449,0.0005979344,0.00004863396,0.0001988396,0.00113985,0.001199261,0.0002809972,0.2511564,0.7438099,0.0000985151],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0002549371,0.001607633,0.0004459835,0.9895271,0.003173929,0.000004177366,0.00001360888,0.00001852358,0.004954113],"genre_scores_gemma":[0.03985984,0.01436564,0.003766489,0.8829327,0.04338562,0.00004118261,0.00007465418,0.0001062217,0.01546774],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.02867102,"threshold_uncertainty_score":0.1508049,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2333798253","doi":"10.1097/00005650-200308000-00004","title":"Physician and Practice Characteristics Associated with the Early Utilization of New Prescription Drugs","year":2003,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":138,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"McGill University","funders":"","keywords":"Medical prescription; Medicine; MEDLINE; Intensive care medicine; Family medicine; Pharmacology; Political science","authors":[{"name":"Robyn Tamblyn","is_ca":true},{"name":"Peter J. McLeod","is_ca":false},{"name":"James A. Hanley","is_ca":false},{"name":"Nadyne Girard","is_ca":false},{"name":"Jeremiah Hurley","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05608320431829633,"gpt":0.2916851483422187,"spread":0.2356019440239224,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005799319,0.0001656833,0.0001559716,0.0009333952,0.0003357878,0.0004358152,0.0002822729,0.0004618158,0.002037995],"category_scores_gemma":[0.003949002,0.000153856,0.0002308516,0.001074653,0.0002908746,0.0002040589,0.0002336463,0.0003852569,0.0001411843],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001184268,"about_ca_system_score_gemma":0.001472059,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1611126,"about_ca_topic_score_gemma":0.2523496,"domain_scores_codex":[0.9994141,0.0001118537,0.00005484615,0.00009192862,0.00018474,0.0001425208],"domain_scores_gemma":[0.9925356,0.001057889,0.004544132,0.0001111884,0.000751682,0.0009994913],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00001430605,0.000008917338,0.9994985,0.000002571222,0.000006712071,0.00002313368,0.00001494259,0.0000208658,0.00004114956,0.000002244537,0.0000346235,0.0003319625],"study_design_scores_gemma":[0.000001013669,0.00001104826,0.9998142,0.00000203518,0.000002025812,0.00006390418,0.00001765895,0.00004969819,0.00000818643,0.000001213437,0.00002851321,5.933296e-7],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9987717,0.0003205684,0.00006550166,0.00009842064,0.000002621541,0.00001362835,0.0003690518,0.00000382797,0.0003545829],"genre_scores_gemma":[0.9994119,0.0001048965,0.00008196738,0.00001916933,0.000006485381,0.00000576006,0.000269913,7.333704e-7,0.00009911483],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1611126,"threshold_uncertainty_score":0.3203495,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3195451158","doi":"10.1080/00207543.2021.1950937","title":"Data analytics in pharmaceutical supply chains: state of the art, opportunities, and challenges","year":2021,"lang":"en","type":"article","venue":"International Journal of Production Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":129,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Polytechnique Montréal","funders":"","keywords":"Supply chain; Analytics; Scopus; Data science; Computer science; Supply chain management; Economic shortage; Big data; Data analysis; Knowledge management; Business; Data mining; MEDLINE; Marketing; Government (linguistics)","authors":[{"name":"Angie Nguyen","is_ca":false},{"name":"Samir Lamouri","is_ca":false},{"name":"Robert Pellerin","is_ca":true},{"name":"Simón Tamayo","is_ca":false},{"name":"Béranger Lekens","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.6582236673124685,"gpt":0.4682280153456835,"spread":0.189995651966785,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03522533,0.0009718483,0.002080024,0.01473192,0.001533087,0.0117178,0.002931958,0.00267753,0.002435417],"category_scores_gemma":[0.07557087,0.0008926538,0.002105747,0.03089698,0.004157702,0.02333462,0.004385752,0.004501962,0.0009914474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003459647,"about_ca_system_score_gemma":0.009915173,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005071792,"about_ca_topic_score_gemma":0.004834702,"domain_scores_codex":[0.9710413,0.01576969,0.003406862,0.002316596,0.006763178,0.0007023527],"domain_scores_gemma":[0.7453597,0.2221384,0.008500766,0.005425004,0.01701719,0.001558871],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001607863,0.0001422999,0.01929918,0.04736897,0.0004950385,0.0003478745,0.003548418,0.008104613,0.0008390071,0.1097721,0.02482239,0.7850993],"study_design_scores_gemma":[0.00005180229,0.0002325606,0.01038163,0.09309997,0.0004744323,0.0009149195,0.02506399,0.02619691,0.002288402,0.3192471,0.5217654,0.0002829398],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01591994,0.8317223,0.05442391,0.08200707,0.001170101,0.0002848718,0.002732799,0.0002745839,0.01146439],"genre_scores_gemma":[0.1324016,0.7728339,0.08192971,0.00578175,0.00280622,0.000408656,0.002940029,0.0001321484,0.0007659677],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.03522533,"threshold_uncertainty_score":0.1862916,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3095635585","doi":"10.1136/bmjgh-2020-002640","title":"Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries","year":2020,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":128,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; McMaster University; Population Health Research Institute; Simon Fraser University","funders":"Faculty of Medicine and Health, University of Sydney; McMaster University; Hamilton Health Sciences","keywords":"Low and middle income countries; Income distribution; High income countries; Comprehensive income; Economics; Adjusted gross income; Business; Public economics; Gross income; Economic growth; Developing country; Inequality","authors":[{"name":"Clara K Chow","is_ca":false},{"name":"Tu Ngoc Nguyen","is_ca":false},{"name":"Simone Marschner","is_ca":false},{"name":"Rafael Díaz","is_ca":false},{"name":"Omar Rahman","is_ca":false},{"name":"Álvaro Avezum","is_ca":false},{"name":"Scott A. Lear","is_ca":true},{"name":"Koon Teo","is_ca":true},{"name":"Karen Yeates","is_ca":true},{"name":"Fernando Laņas","is_ca":false},{"name":"Wei Li","is_ca":false},{"name":"Bo Hu","is_ca":false},{"name":"Patricio López‐Jaramillo","is_ca":false},{"name":"Rajeev Gupta","is_ca":false},{"name":"Rajesh Kumar","is_ca":false},{"name":"Prem Mony","is_ca":false},{"name":"Ahmad Bahonar","is_ca":false},{"name":"Khalid Yusoff","is_ca":false},{"name":"Rasha Khatib","is_ca":false},{"name":"Khawar Kazmi","is_ca":false},{"name":"Antonio L Dans","is_ca":false},{"name":"Katarzyna Zatońska","is_ca":false},{"name":"Khalid F. AlHabib","is_ca":false},{"name":"Iolanthé M. Kruger","is_ca":false},{"name":"Annika Rosengren","is_ca":false},{"name":"Sadi Güleç","is_ca":false},{"name":"Afzalhussein Yusufali","is_ca":false},{"name":"Jephat Chifamba","is_ca":false},{"name":"Sumathy Rangarajan","is_ca":true},{"name":"Martin McKee","is_ca":false},{"name":"Salim Yusuf","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04375054261232827,"gpt":0.3226200611086289,"spread":0.2788695184963006,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001189716,0.0003605937,0.000392319,0.001097242,0.0005659199,0.001029463,0.0003899065,0.0005279014,0.001325392],"category_scores_gemma":[0.002377321,0.0003948211,0.0008115213,0.001716713,0.000545671,0.0005765315,0.001400104,0.0005516162,0.0001472648],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003410233,"about_ca_system_score_gemma":0.0003740626,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009858482,"about_ca_topic_score_gemma":0.009416463,"domain_scores_codex":[0.9990724,0.0004170418,0.0001053848,0.0001383792,0.00009377774,0.0001730405],"domain_scores_gemma":[0.9981135,0.0002900295,0.001116725,0.00008547826,0.000105408,0.0002889043],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00005909062,0.00002765935,0.9993483,0.000014456,0.00006814546,0.00003407596,0.00006215915,0.00003538531,0.00003219019,0.00001187338,0.00003178608,0.0002747753],"study_design_scores_gemma":[0.000009903315,0.00007436779,0.9992461,0.00001039362,0.00003973388,0.00008577142,0.0003022285,0.0001088359,0.0000196651,0.00001478962,0.00008480522,0.000003447367],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9991992,0.0001926109,0.00003802563,0.00002834003,0.000002445749,0.000008007726,0.0003781601,0.000001020757,0.0001521529],"genre_scores_gemma":[0.9995479,0.00008277908,0.00004584282,0.00001571582,0.000004491455,0.000008818735,0.0002536886,5.083837e-7,0.00004010757],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009858482,"threshold_uncertainty_score":0.01960224,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3011937804","doi":"10.1080/16549716.2019.1694745","title":"The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk","year":2020,"lang":"en","type":"review","venue":"Global Health Action","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":121,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"World Health Organization","keywords":"Transparency (behavior); Procurement; Accountability; Language change; Business; Corporate governance; Accounting; Public relations; Public economics; Economics; Finance; Marketing; Political science; Law","authors":[{"name":"Jillian Clare Köhler","is_ca":true},{"name":"Deirdre Dimancesco","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2756753538574691,"gpt":0.4388084882619515,"spread":0.1631331344044825,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03142323,0.0005010269,0.0006795478,0.002765304,0.006654937,0.01989022,0.001700118,0.005854296,0.005807816],"category_scores_gemma":[0.05442514,0.0004866535,0.001153534,0.003477155,0.01585114,0.01580555,0.006890633,0.005712482,0.0008730986],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01326563,"about_ca_system_score_gemma":0.02538042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007156572,"about_ca_topic_score_gemma":0.00929292,"domain_scores_codex":[0.959592,0.02857234,0.00128044,0.001202231,0.00545393,0.003899066],"domain_scores_gemma":[0.9207851,0.04852647,0.01662207,0.002827393,0.008432914,0.00280608],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001333436,0.0002411857,0.0182123,0.003339538,0.0001908933,0.001664658,0.02212605,0.003448912,0.0005145264,0.7898962,0.02843056,0.131802],"study_design_scores_gemma":[0.00007065475,0.0003433818,0.02083422,0.02281741,0.0002563084,0.001724939,0.0447264,0.0036268,0.002222955,0.5941336,0.3090133,0.0002300189],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.07393509,0.09491808,0.03245781,0.5975183,0.002019487,0.0004541101,0.0001559651,0.0001435908,0.1983975],"genre_scores_gemma":[0.8984238,0.06335144,0.009284304,0.01977596,0.000984864,0.0002102129,0.00006687759,0.00005903806,0.007843555],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.03142323,"threshold_uncertainty_score":0.1661839,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205704930","doi":"10.1038/s41574-021-00621-y","title":"Global accessibility of therapeutics for diabetes mellitus","year":2022,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":118,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Sinai Health System; University of Toronto","funders":"NIHR Leicester Biomedical Research Centre; Madras Diabetes Research Foundation; Universidade Federal do Rio Grande do Sul; University of Toronto; National Institute for Health and Care Research","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Type 2 Diabetes Mellitus; Health care; Endocrinology; Economic growth","authors":[{"name":"Michael Fralick","is_ca":true},{"name":"Alicia J. Jenkins","is_ca":false},{"name":"Kamlesh Khunti","is_ca":false},{"name":"Jean Claude Mbanya","is_ca":false},{"name":"Viswanathan Mohan","is_ca":false},{"name":"María Inês Schmidt","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1931444438650594,"gpt":0.4247148174847424,"spread":0.231570373619683,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002267854,0.0007585099,0.001740954,0.002965258,0.0001564837,0.00163354,0.0005485697,0.001416103,0.008426306],"category_scores_gemma":[0.006037884,0.000310277,0.0008361107,0.004281525,0.0008527125,0.002255745,0.00142311,0.001967218,0.001204811],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001808759,"about_ca_system_score_gemma":0.002584705,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003426532,"about_ca_topic_score_gemma":0.005321978,"domain_scores_codex":[0.9990724,0.0003313261,0.0001063892,0.0001021774,0.000305266,0.00008241171],"domain_scores_gemma":[0.9958127,0.002824801,0.0007796237,0.00008918118,0.0003779132,0.0001158032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001233841,0.00003273325,0.0005004198,0.01504868,0.0003409611,0.00009494821,0.00003622628,0.001229848,0.0002170015,0.0248411,0.0352282,0.9223065],"study_design_scores_gemma":[0.0000944722,0.0001074895,0.007945697,0.02943204,0.0007961144,0.0009817639,0.0001267044,0.00045604,0.0003092987,0.03252532,0.9271841,0.0000410364],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001087502,0.9966447,0.0001615626,0.001549226,0.0001448293,0.00000183273,0.00005610287,0.000004873802,0.001328159],"genre_scores_gemma":[0.001984229,0.9969419,0.00009667049,0.0003998284,0.000352502,0.00000337737,0.00003463768,0.000001904536,0.0001850853],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008426306,"threshold_uncertainty_score":0.02818882,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4256136035","doi":"10.1212/01.wnl.0000313154.55518.25","title":"Clinical consequences of generic substitution of lamotrigine for patients with epilepsy","year":2008,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":117,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Lamotrigine; Medicine; Epilepsy; Gabapentin; Carbamazepine; Pharmacy; Psychiatry; Family medicine; Alternative medicine","authors":[{"name":"Jacques LeLorier","is_ca":true},{"name":"Mei Sheng Duh","is_ca":true},{"name":"Pierre Emmanuel Paradis","is_ca":true},{"name":"Patrick Lefèbvre","is_ca":true},{"name":"J. Weiner","is_ca":true},{"name":"R Manjunath","is_ca":true},{"name":"O. Sheehy","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1028178724892148,"gpt":0.3094421319751415,"spread":0.2066242594859267,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006043631,0.0001221138,0.0002032738,0.0003627828,0.0004063342,0.0005188282,0.0002631096,0.0003748357,0.002288221],"category_scores_gemma":[0.006618509,0.0001052351,0.0003534236,0.0009387844,0.0002856691,0.0002826298,0.0003157408,0.0004636421,0.0001385316],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0020015,"about_ca_system_score_gemma":0.00114102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.05666453,"about_ca_topic_score_gemma":0.08519173,"domain_scores_codex":[0.9991657,0.0002154268,0.0001123298,0.0001008597,0.0002333619,0.0001723945],"domain_scores_gemma":[0.9950885,0.0006880826,0.0033259,0.0001010793,0.0003632336,0.0004332925],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003226587,0.00004333304,0.9928838,0.0000215657,0.00006443895,0.0003147203,0.00004591299,0.0001099385,0.0001909174,0.00002263094,0.0002983255,0.005681833],"study_design_scores_gemma":[0.00001505621,0.00008304153,0.9987515,0.00001046697,0.00002426207,0.0005948999,0.000112091,0.0001705962,0.00004137939,0.00001515708,0.0001785786,0.000002951626],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967938,0.0008350262,0.00004295406,0.0005926479,0.000008163054,0.00001306396,0.0004675771,0.000003859717,0.001242908],"genre_scores_gemma":[0.9992765,0.0001734234,0.0000412799,0.0001734688,0.00001211864,0.000002870124,0.0002531794,9.443064e-7,0.00006621639],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05666453,"threshold_uncertainty_score":0.1126694,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2589088062","doi":"10.1016/j.healthpol.2017.02.002","title":"Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia","year":2017,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":114,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"University of British Columbia; Commonwealth Fund","keywords":"Confidentiality; Negotiation; Business; Statutory law; Discounting; Public health; Revenue; Public economics; Actuarial science; Marketing; Economics; Law; Finance; Medicine; Political science; Nursing","authors":[{"name":"Steven G. Morgan","is_ca":true},{"name":"Sabine Vogler","is_ca":false},{"name":"Anita K. Wagner","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1511648610852986,"gpt":0.3988349864480218,"spread":0.2476701253627232,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00807242,0.0001377728,0.0003270413,0.0008519511,0.001623632,0.002258391,0.0004994149,0.001037473,0.002406202],"category_scores_gemma":[0.02862065,0.000452639,0.0003916773,0.0011169,0.001584414,0.002039086,0.00198453,0.001738792,0.0001848561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002027109,"about_ca_system_score_gemma":0.002655282,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02111834,"about_ca_topic_score_gemma":0.01835447,"domain_scores_codex":[0.9933649,0.003551532,0.0006379213,0.0002916199,0.001161294,0.0009926407],"domain_scores_gemma":[0.9594565,0.01466205,0.01780229,0.001019088,0.002303383,0.004756585],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001894656,0.0004120791,0.7490684,0.0001351305,0.00006970068,0.0008593689,0.2163466,0.0001619978,0.0009395478,0.0008893221,0.002522374,0.02840611],"study_design_scores_gemma":[0.00003222991,0.0005057154,0.6935744,0.0001968241,0.00002615634,0.001150245,0.2938584,0.0005935842,0.0002450249,0.0003569855,0.009393859,0.00006657494],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972516,0.000184472,0.00007019779,0.001389111,0.000007007883,0.00001191928,0.00003601644,0.000002230007,0.001047419],"genre_scores_gemma":[0.9990327,0.0001933488,0.00007205141,0.0004588531,0.00001109764,0.000008014383,0.00002380127,0.000001810885,0.0001983286],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02111834,"threshold_uncertainty_score":0.04269153,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2043816730","doi":"10.1016/j.jval.2012.09.004","title":"What Is Wrong with Orphan Drug Policies?","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":110,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"","keywords":"Orphan drug; Business; Bioinformatics; Biology","authors":[{"name":"André Côté","is_ca":true},{"name":"Bernard Keating","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1068436613679914,"gpt":0.3290383906729973,"spread":0.2221947293050059,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02855508,0.0005774504,0.002157992,0.002092417,0.002180861,0.01025903,0.002049425,0.01091825,0.00901278],"category_scores_gemma":[0.1435919,0.0004038273,0.001130059,0.002497967,0.01695833,0.01889801,0.003115146,0.01172675,0.000739492],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006187821,"about_ca_system_score_gemma":0.008356446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006935987,"about_ca_topic_score_gemma":0.00620081,"domain_scores_codex":[0.9714285,0.01773258,0.00121995,0.001722164,0.005857929,0.002038922],"domain_scores_gemma":[0.8909903,0.08146923,0.009200776,0.004517791,0.00872993,0.005091883],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.0002855666,0.0001147534,0.005010548,0.0004526115,0.000301369,0.0002927236,0.0004667712,0.001358549,0.00008503019,0.8653489,0.05865476,0.06762845],"study_design_scores_gemma":[0.0000731992,0.00003902282,0.001330119,0.0008512036,0.00006870032,0.0001626227,0.000464246,0.0009012703,0.0001366037,0.9447521,0.05119564,0.00002525081],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0138203,0.02848578,0.003786208,0.9140924,0.004990003,0.00001451937,0.0003049657,0.0000475784,0.03445827],"genre_scores_gemma":[0.6801578,0.03573918,0.003748533,0.2545269,0.01847232,0.00008699647,0.0002211121,0.0001221805,0.006925015],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.02855508,"threshold_uncertainty_score":0.1510155,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2071885854","doi":"10.1136/bmj.38582.703866.ae","title":"“Breakthrough” drugs and growth in expenditure on prescription drugs in Canada","year":2005,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":107,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"","keywords":"Medical prescription; Medicine; Drug industry; Computer science; Data science; Pharmacology; Biology; Biotechnology","authors":[{"name":"Steven G. Morgan","is_ca":true},{"name":"Kenneth Bassett","is_ca":true},{"name":"James M Wright","is_ca":true},{"name":"Robert G. Evans","is_ca":true},{"name":"Morris L. Barer","is_ca":true},{"name":"Patrícia Caetano","is_ca":true},{"name":"Charlyn Black","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03016981947161768,"gpt":0.2681968652973627,"spread":0.238027045825745,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009341487,0.0003882135,0.0005517327,0.003972096,0.002536842,0.002537711,0.00117818,0.001103612,0.007371022],"category_scores_gemma":[0.009823175,0.0003395994,0.0007747635,0.01297253,0.001064576,0.0010652,0.001497641,0.001983869,0.0004092187],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.1192749,"about_ca_system_score_gemma":0.1003089,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9984114,"about_ca_topic_score_gemma":0.9982829,"domain_scores_codex":[0.9979961,0.0001182177,0.0001040059,0.0001375167,0.0007608592,0.0008833717],"domain_scores_gemma":[0.9887723,0.0009109934,0.002130663,0.0001707751,0.005533766,0.002481432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003886812,0.000139052,0.8602194,0.0003284075,0.0002422192,0.0006773389,0.001138577,0.005606617,0.000182856,0.01551983,0.08516999,0.03038698],"study_design_scores_gemma":[0.00006017709,0.0000265599,0.967165,0.0002978549,0.0001288543,0.0001661454,0.001892668,0.006909349,0.0002367088,0.001414956,0.02164444,0.0000572338],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8184055,0.01453283,0.0006203054,0.04623874,0.0003453873,0.0001097013,0.07898232,0.000159379,0.04060592],"genre_scores_gemma":[0.9718536,0.007558336,0.0004004219,0.001096474,0.0001008263,0.00002389653,0.01293266,0.00003332009,0.006000571],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8807251,"threshold_uncertainty_score":0.8654043,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1973148128","doi":"10.1208/s12248-009-9142-z","title":"Bioequivalence; Its History, Practice, and Future","year":2009,"lang":"en","type":"review","venue":"The AAPS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":107,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Bioequivalence; Pharmaceutical industry; Business; Quality (philosophy); Management science; Risk analysis (engineering); Engineering ethics; Medicine; Pharmacology; Engineering","authors":[{"name":"Kamal K. Midha","is_ca":true},{"name":"Gordon McKay","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1733265012009086,"gpt":0.3625870007169042,"spread":0.1892604995159956,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005913594,0.0007052688,0.002390415,0.00281595,0.0005327726,0.003774442,0.001336209,0.004146439,0.004112965],"category_scores_gemma":[0.01067234,0.0004972069,0.0005869903,0.006534301,0.003526869,0.004089299,0.0009218889,0.004678144,0.001222499],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00359079,"about_ca_system_score_gemma":0.005655775,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005116563,"about_ca_topic_score_gemma":0.007986861,"domain_scores_codex":[0.9979505,0.0007835224,0.0002209306,0.0002870981,0.0006791739,0.00007882805],"domain_scores_gemma":[0.9888758,0.007977662,0.001080708,0.0002344279,0.001485854,0.0003454716],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001520788,0.000115434,0.0004742958,0.007939331,0.00008856579,0.0001145114,0.0001239388,0.0006055832,0.0003073287,0.02988514,0.02206149,0.9381323],"study_design_scores_gemma":[0.00006619037,0.0001895816,0.002665541,0.01317327,0.0001712735,0.001974585,0.0003156866,0.0005841472,0.0004637408,0.03944649,0.9408879,0.00006152347],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007972706,0.9968119,0.0001224524,0.002314495,0.0000968307,0.00000125872,0.000006548267,0.000002156646,0.0005645215],"genre_scores_gemma":[0.002485363,0.9958158,0.0002306164,0.0008070804,0.0004042453,0.00000405576,0.000007939361,0.000001868757,0.0002431504],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005913594,"threshold_uncertainty_score":0.0312745,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2045226478","doi":"10.2165/00019053-200523120-00002","title":"Comment on ???The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development???","year":2005,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":104,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Institute of Health Economics","funders":"","keywords":"Drug development; Drug; Pharmaceutical industry; Competition (biology); Drug class; Medicine; Marketing; Pharmacology; Business; Actuarial science","authors":[{"name":"Aidan Hollis","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1738690385591195,"gpt":0.3662685802299175,"spread":0.1923995416707981,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008057238,0.001054002,0.002432694,0.00127118,0.004376702,0.006700984,0.003577323,0.1055219,0.01031193],"category_scores_gemma":[0.0402012,0.001273422,0.002039575,0.001614293,0.003360989,0.004982166,0.002035453,0.05021001,0.00817336],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01025746,"about_ca_system_score_gemma":0.009346694,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.05127515,"about_ca_topic_score_gemma":0.07451937,"domain_scores_codex":[0.9946044,0.001130006,0.0008327512,0.0008344676,0.001370668,0.001227653],"domain_scores_gemma":[0.9796907,0.01265421,0.001864522,0.0005076418,0.002939349,0.002343655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000819176,0.00002902419,0.0006951816,0.00004289636,0.00001963514,0.0003695296,0.0001010907,0.00007081425,0.00006267766,0.002874571,0.9930028,0.002649873],"study_design_scores_gemma":[0.00027758,0.0001375924,0.006919201,0.0006326878,0.000123309,0.000632227,0.00102612,0.001111662,0.0004476534,0.01516933,0.9733334,0.0001891576],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0003523272,0.0005126563,0.0000670012,0.9843537,0.01163191,0.00001624636,0.0002893733,0.00002274739,0.002754014],"genre_scores_gemma":[0.001720182,0.0002765244,0.00007874183,0.9781842,0.01299705,0.00002706157,0.00003842998,0.00001343937,0.006664543],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.1055219,"threshold_uncertainty_score":0.1019534,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2173121992","doi":"10.1200/jco.2015.61.8736","title":"Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"National Cancer Institute; National Institutes of Health; World Health Organization","keywords":"Medicine; Cancer; Intensive care medicine; Internal medicine","authors":[{"name":"Lawrence N. Shulman","is_ca":true},{"name":"Claire Wagner","is_ca":true},{"name":"Ronald D. Barr","is_ca":true},{"name":"Gilberto Lopes","is_ca":true},{"name":"Giuseppe Longo","is_ca":true},{"name":"Jane Robertson","is_ca":true},{"name":"Gilles Forte","is_ca":true},{"name":"Julie Torode","is_ca":true},{"name":"Nicola Magrini","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.6455804736146742,"gpt":0.6181926204129479,"spread":0.02738785320172632,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.158791,0.002009964,0.001343448,0.009337554,0.003682557,0.01348411,0.003267777,0.002922999,0.004911731],"category_scores_gemma":[0.158586,0.0008331903,0.002321973,0.01139017,0.008091583,0.01195282,0.008884374,0.005182476,0.001223965],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01915142,"about_ca_system_score_gemma":0.06086988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006669427,"about_ca_topic_score_gemma":0.01135428,"domain_scores_codex":[0.8851935,0.07727363,0.008080149,0.004858432,0.02262496,0.00196933],"domain_scores_gemma":[0.8192464,0.1056488,0.02687585,0.0100182,0.03458884,0.003621863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002851476,0.00103222,0.01779757,0.02949288,0.0005435014,0.0003023587,0.01101003,0.00675938,0.001695218,0.2913984,0.0384493,0.601234],"study_design_scores_gemma":[0.0004142023,0.001290107,0.01510181,0.03480642,0.001056763,0.0004180944,0.01817064,0.0147612,0.01015463,0.4503915,0.4530911,0.0003436196],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"review","genre_scores_codex":[0.04268466,0.09083783,0.4497646,0.2463127,0.003413101,0.02894217,0.004066234,0.0008953217,0.1330832],"genre_scores_gemma":[0.2099939,0.0505233,0.7061423,0.01324732,0.001345668,0.01097519,0.002090863,0.0001778943,0.005503627],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.158791,"threshold_uncertainty_score":0.8397772,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2031692846","doi":"10.1211/ijpp.17.02.0002","title":"Consumers' views on generic medicines: A review of the literature","year":2009,"lang":"en","type":"review","venue":"International Journal of Pharmacy Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; MEDLINE; Reimbursement; Grey literature; Scopus; Health care; Seriousness; Family medicine; Public relations; Political science","authors":[{"name":"Mohamed Azmi Hassali","is_ca":false},{"name":"Asrul Akmal Shafie","is_ca":false},{"name":"Shazia Jamshed","is_ca":false},{"name":"Mohamed Izham Mohamed Ibrahim","is_ca":false},{"name":"Ahmed Awaisu","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1851946808773101,"gpt":0.4623296083132797,"spread":0.2771349274359696,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005263286,0.0005481006,0.001588225,0.008890255,0.0004148121,0.001759668,0.0007328738,0.001681509,0.002921427],"category_scores_gemma":[0.01411284,0.0004827358,0.001097437,0.009500128,0.000822569,0.002978123,0.0007086567,0.0006757656,0.0003365647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001562968,"about_ca_system_score_gemma":0.003055169,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003493946,"about_ca_topic_score_gemma":0.009028314,"domain_scores_codex":[0.9968681,0.001077429,0.0009537746,0.0002104099,0.0007928348,0.00009739128],"domain_scores_gemma":[0.9843018,0.01097015,0.002880464,0.00008526865,0.001592583,0.0001697198],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0004391465,0.0001148494,0.01319151,0.5289569,0.001253414,0.001571915,0.006663038,0.0001114766,0.0009069922,0.0009414396,0.01077559,0.4350736],"study_design_scores_gemma":[0.000143683,0.0008687895,0.1038739,0.71144,0.006370914,0.009672984,0.01934218,0.0001829904,0.0006048974,0.001022626,0.1463543,0.0001227533],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.005530463,0.9925973,0.00004898357,0.0009331539,0.00009108461,0.00002228666,0.0001108656,0.000001853927,0.0006639322],"genre_scores_gemma":[0.02460505,0.9739254,0.0002509015,0.0008233077,0.0001341603,0.00004755616,0.0001015283,0.000001322178,0.0001107201],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008890255,"threshold_uncertainty_score":0.02783525,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2582303529","doi":"10.1371/journal.pmed.1002191","title":"What Is the Purpose of the Orphan Drug Act?","year":2017,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Orphan drug; Drug; Medicine; Pharmacology; Bioinformatics; Biology","authors":[{"name":"Matthew Herder","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09471316794752938,"gpt":0.3094459043501145,"spread":0.2147327364025851,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02013431,0.000536371,0.001134112,0.001183986,0.004469348,0.01032929,0.00221674,0.0193681,0.006886128],"category_scores_gemma":[0.06058137,0.0004266441,0.001123901,0.001358078,0.01305487,0.01252018,0.00272669,0.02224509,0.002696692],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005593613,"about_ca_system_score_gemma":0.01673085,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02826189,"about_ca_topic_score_gemma":0.02832078,"domain_scores_codex":[0.9860166,0.005264437,0.0008294792,0.001344008,0.004816646,0.001728843],"domain_scores_gemma":[0.9625508,0.02577898,0.001967285,0.001511201,0.005700232,0.00249158],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.00007019631,0.00003062065,0.0009853224,0.000127339,0.00002594298,0.0001448966,0.0005794975,0.0001166331,0.0001145852,0.5543457,0.425655,0.01780422],"study_design_scores_gemma":[0.00002470223,0.00003821171,0.001319775,0.0006590802,0.00003114288,0.0001354838,0.000897327,0.0002394289,0.0003329902,0.08446585,0.9117857,0.00007035742],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.0009022794,0.009775503,0.0006586521,0.9622957,0.008146076,0.000007627874,0.00009214192,0.00003773561,0.01808434],"genre_scores_gemma":[0.03722741,0.01329157,0.001694584,0.9150284,0.006768481,0.00005317356,0.0001034759,0.0001086252,0.02572431],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02826189,"threshold_uncertainty_score":0.1064817,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121098095","doi":"10.1016/j.healthpol.2003.07.007","title":"The effect of generic competition on the price of brand-name drugs","year":2003,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":100,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; York University; University Health Network","funders":"","keywords":"Competition (biology); Formulary; Competitor analysis; Brand names; Business; Generic drug; Product (mathematics); Market share; Government (linguistics); Marketing; Economics; Advertising; Medicine","authors":[{"name":"Joel Lexchin","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04911101962320849,"gpt":0.333015503694424,"spread":0.2839044840712155,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005908175,0.0005056985,0.001440476,0.00162941,0.001036645,0.006451678,0.001066076,0.00732266,0.01481957],"category_scores_gemma":[0.036571,0.0008315,0.001856791,0.001977156,0.002859169,0.003978597,0.001198478,0.004946805,0.0008543896],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008061275,"about_ca_system_score_gemma":0.003570237,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03128559,"about_ca_topic_score_gemma":0.02654864,"domain_scores_codex":[0.9951754,0.002175262,0.000217246,0.0003967636,0.0005927726,0.0014425],"domain_scores_gemma":[0.9566133,0.03304323,0.005926048,0.0006992683,0.001651146,0.002067026],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","study_design_scores_codex":[0.01549482,0.00208773,0.171739,0.001356709,0.001805387,0.002944602,0.0007645743,0.111288,0.008739907,0.5688441,0.04605987,0.06887525],"study_design_scores_gemma":[0.003873139,0.004242681,0.4725018,0.0003262566,0.003119681,0.001441598,0.001811283,0.1352875,0.007152596,0.3256195,0.04410357,0.0005204997],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8311237,0.01211963,0.004547502,0.0748941,0.0006367042,0.00007718134,0.003255495,0.0001655632,0.07318016],"genre_scores_gemma":[0.991981,0.001615435,0.0002817215,0.002154123,0.0005325318,0.000007605502,0.0001852275,0.00001321548,0.003229111],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03128559,"threshold_uncertainty_score":0.06220698,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2104400639","doi":"10.1503/cmaj.141564","title":"Estimated cost of universal public coverage of prescription drugs in Canada","year":2015,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":97,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true},"ca_institutions":"Women's College Hospital; University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research; Health Canada; Michael Smith Health Research BC","keywords":"Medical prescription; Government (linguistics); Prescription drug; Business; Public health; Public economics; Medicine; Economics; Pharmacology","authors":[{"name":"Steven G. Morgan","is_ca":true},{"name":"Michael R. Law","is_ca":true},{"name":"Jamie R. Daw","is_ca":true},{"name":"Liza Abraham","is_ca":true},{"name":"Danielle Martin","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04436535506075406,"gpt":0.2471488685197388,"spread":0.2027835134589847,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009369507,0.0009240065,0.0005059393,0.003347788,0.0009371199,0.001830869,0.001236837,0.0004895519,0.003689391],"category_scores_gemma":[0.006046683,0.0003966644,0.001617304,0.005464834,0.0004536793,0.0006447088,0.0008039943,0.000875897,0.0003125076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.08944543,"about_ca_system_score_gemma":0.04924428,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9852004,"about_ca_topic_score_gemma":0.9780785,"domain_scores_codex":[0.998063,0.000225031,0.0001029876,0.0001254801,0.001113761,0.0003696483],"domain_scores_gemma":[0.9956627,0.0004719278,0.0004638824,0.00008991082,0.003120352,0.0001912404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.0004221926,0.0001108742,0.3934047,0.001365453,0.001607274,0.0008791378,0.0002985117,0.4613082,0.000750317,0.01960493,0.03315112,0.08709744],"study_design_scores_gemma":[0.0002332097,0.0001671074,0.5473206,0.0009497944,0.001275469,0.001048459,0.0009940705,0.3572152,0.002705841,0.005820965,0.08205201,0.0002172547],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6556869,0.01315457,0.01242588,0.005812631,0.0002031253,0.0006624601,0.22091,0.0007266485,0.09041782],"genre_scores_gemma":[0.9595306,0.004254558,0.005618352,0.0002800632,0.00003447339,0.0001384537,0.02421809,0.00005175913,0.005873838],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08944543,"threshold_uncertainty_score":0.6489751,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2096918198","doi":"10.1212/01.wnl.0000349653.30398.e8","title":"CLINICAL CONSEQUENCES OF GENERIC SUBSTITUTION OF LAMOTRIGINE FOR PATIENTS WITH EPILEPSY","year":2009,"lang":"en","type":"letter","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":95,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Lamotrigine; Epilepsy; Substitution (logic); Medicine; Clinical neurology; Psychiatry; Psychology; Neuroscience; Computer science","authors":[{"name":"Laura S. Boylan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07985443588549204,"gpt":0.3069363065674907,"spread":0.2270818706819987,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001105652,0.000163246,0.0003034923,0.000396098,0.001233139,0.0009175739,0.0004523644,0.006488112,0.003996509],"category_scores_gemma":[0.01326904,0.0001337087,0.0003721753,0.0006884011,0.0008772605,0.0005790283,0.0003229346,0.003385874,0.0007702021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005509167,"about_ca_system_score_gemma":0.002258702,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02542795,"about_ca_topic_score_gemma":0.06442478,"domain_scores_codex":[0.9991927,0.000285334,0.00009209821,0.00007510588,0.0001712661,0.0001835047],"domain_scores_gemma":[0.9926046,0.004458942,0.001141975,0.0001884031,0.0008363762,0.0007696532],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.001653377,0.0005446813,0.2989778,0.0001859639,0.0001223833,0.1773995,0.001046081,0.001589792,0.001828222,0.009856209,0.4190438,0.08775224],"study_design_scores_gemma":[0.001194885,0.001596044,0.4877864,0.0008919649,0.0002398682,0.2070628,0.00449201,0.01477369,0.001562211,0.02763019,0.252537,0.0002330285],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.1298932,0.00321386,0.0003731751,0.832522,0.00162698,0.00006212567,0.0003602081,0.00003461622,0.03191387],"genre_scores_gemma":[0.6556641,0.002449485,0.0004305676,0.3264675,0.008516824,0.00002592159,0.0001771543,0.00001469701,0.006253605],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02542795,"threshold_uncertainty_score":0.05055988,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3056551509","doi":"10.3389/fmed.2020.00457","title":"The World Health Organization Global Benchmarking Tool an Instrument to Strengthen Medical Products Regulation and Promote Universal Health Coverage","year":2020,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":94,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hamilton Health Sciences","funders":"World Health Organization","keywords":"Benchmarking; Business; Process management; Knowledge management; Engineering management; Computer science; Engineering; Marketing","authors":[{"name":"Alireza Khadem Broojerdi","is_ca":false},{"name":"Hiiti Sillo","is_ca":false},{"name":"Razieh Ostad Ali Dehaghi","is_ca":false},{"name":"Mike Ward","is_ca":false},{"name":"Mohamed Refaat","is_ca":false},{"name":"Jane Parry","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03681927475095572,"gpt":0.2817846207367667,"spread":0.244965345985811,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03519553,0.001463759,0.001064283,0.01448423,0.001131016,0.00438828,0.001480769,0.001019988,0.01043318],"category_scores_gemma":[0.07215669,0.0004077068,0.001343956,0.01977803,0.001071104,0.005755688,0.005848153,0.001687489,0.001713203],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00341077,"about_ca_system_score_gemma":0.01174337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005915969,"about_ca_topic_score_gemma":0.003492429,"domain_scores_codex":[0.9669658,0.02055588,0.003353985,0.000978957,0.006771696,0.001373683],"domain_scores_gemma":[0.9564251,0.01684329,0.00742433,0.003230199,0.01342174,0.00265531],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003632523,0.0004719597,0.03393266,0.002890097,0.0003931182,0.0002158571,0.002016757,0.01389147,0.0007445418,0.09293644,0.4453045,0.4068393],"study_design_scores_gemma":[0.0005380169,0.0009547133,0.1199504,0.005588977,0.0003174076,0.0004529973,0.005889766,0.02068841,0.003316008,0.1045979,0.7373312,0.0003742002],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.07597514,0.005774959,0.2925036,0.03078333,0.003734318,0.01049856,0.1106898,0.0108886,0.4591516],"genre_scores_gemma":[0.4375386,0.003649289,0.447931,0.0049356,0.0006124574,0.01710805,0.07171778,0.001570895,0.01493636],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.03519553,"threshold_uncertainty_score":0.186134,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2022778498","doi":"10.3386/w16431","title":"Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation","year":2010,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":93,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Competition (biology); Legislation; Loyalty; Business; Brand loyalty; Industrial organization; Advertising; Marketing; Commerce; Economics","authors":[{"name":"Ernst R. Berndt","is_ca":false},{"name":"Murray Aitken","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.3011440009757697,"gpt":0.4848980425436471,"spread":0.1837540415678774,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001388236,0.00008907753,0.0002810412,0.001256217,0.00113947,0.003235728,0.0003742549,0.001361523,0.002704001],"category_scores_gemma":[0.004950203,0.0001407233,0.0003239441,0.002386309,0.00141895,0.002470488,0.001217101,0.002022089,0.0002815771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003061876,"about_ca_system_score_gemma":0.00179299,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03593661,"about_ca_topic_score_gemma":0.0528189,"domain_scores_codex":[0.9992439,0.000104211,0.00004986576,0.00009664537,0.0002810022,0.0002244228],"domain_scores_gemma":[0.9963747,0.0006383967,0.001847265,0.0000631143,0.0003808487,0.0006957636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000740915,0.0009655426,0.7608171,0.000276488,0.0001278857,0.0007312104,0.01456324,0.001164305,0.001028891,0.07445206,0.01126373,0.1338687],"study_design_scores_gemma":[0.000007936212,0.0001954557,0.9741813,0.0001530172,0.00002739149,0.0002819475,0.003329376,0.0007223675,0.0002087595,0.003381869,0.01747948,0.00003100395],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9661361,0.009103157,0.0002523306,0.005997181,0.0000820271,0.0000153044,0.0004406752,0.000005716983,0.01796755],"genre_scores_gemma":[0.9888417,0.004645209,0.0001578697,0.002078873,0.0004094008,0.00001338449,0.0004253581,0.000006965325,0.003421194],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03593661,"threshold_uncertainty_score":0.07145488,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2890449704","doi":"10.1080/13571516.2011.584423","title":"Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation","year":2011,"lang":"en","type":"article","venue":"International Journal of the Economics of Business","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":92,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Fell; Quarter (Canadian coin); Legislation; Medical prescription; Brand loyalty; Market share; Generic drug; Competition (biology); Index (typography); Price index; Economics; Business; Advertising; Marketing; Medicine; Drug; Microeconomics","authors":[{"name":"Ernst R. Berndt","is_ca":false},{"name":"Murray Aitken","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04733761495156,"gpt":0.266805689216466,"spread":0.219468074264906,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001282802,0.00005842282,0.000245304,0.000816998,0.0007625152,0.002242641,0.0003481984,0.001055211,0.003648543],"category_scores_gemma":[0.006341517,0.0001047682,0.0002884452,0.001247658,0.0007761358,0.001343915,0.0007818308,0.001708392,0.0003032124],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001828669,"about_ca_system_score_gemma":0.001164217,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0327233,"about_ca_topic_score_gemma":0.04185851,"domain_scores_codex":[0.9994062,0.00007342878,0.00003759356,0.00006195661,0.0002028662,0.0002178046],"domain_scores_gemma":[0.9922543,0.001220281,0.004644846,0.000100794,0.0006497585,0.001129996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004214478,0.0005371018,0.9633436,0.00004755312,0.00007389134,0.0002801043,0.00205534,0.0003284534,0.0003668862,0.00663595,0.003172597,0.02273714],"study_design_scores_gemma":[0.000007092573,0.0001218996,0.9957995,0.0000265818,0.00001483241,0.0000894222,0.001042927,0.0003338904,0.0001207504,0.0004230121,0.002010506,0.000009598337],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928998,0.001103724,0.00004654461,0.002075038,0.00002322073,0.000005468223,0.0002362946,0.00000206883,0.003607866],"genre_scores_gemma":[0.9978765,0.0004254444,0.00001629283,0.0003622659,0.00009253745,0.000002564831,0.0002180506,0.000001478565,0.00100488],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0327233,"threshold_uncertainty_score":0.06506568,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1561889056","doi":"10.3386/w20799","title":"Intellectual Property Rights and Access to Innovation: Evidence from TRIPS","year":2014,"lang":"en","type":"preprint","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":90,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"TRIPS architecture; Intellectual property; Business; Competition (biology); TRIPS Agreement; Price premium; Product (mathematics); International economics; International trade; Drug prices; Industrial organization; Economics; Public economics; Microeconomics","authors":[{"name":"Margaret Kyle","is_ca":false},{"name":"Yi Qian","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.6725693421532669,"gpt":0.5429627906360296,"spread":0.1296065515172373,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00385445,0.0002807798,0.000433352,0.002220584,0.0005786168,0.001671266,0.001074415,0.001117915,0.01284238],"category_scores_gemma":[0.03038523,0.0002262123,0.00147185,0.003540594,0.001962985,0.002293155,0.002899294,0.001760082,0.001181645],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006316229,"about_ca_system_score_gemma":0.0005374246,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01028064,"about_ca_topic_score_gemma":0.006491307,"domain_scores_codex":[0.9977354,0.0008865502,0.0001763548,0.0002721038,0.0005239613,0.0004056891],"domain_scores_gemma":[0.8849327,0.05676719,0.04658167,0.005236803,0.00269582,0.003785811],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003496357,0.001606925,0.8896694,0.00115751,0.002432744,0.001512434,0.00177753,0.0135917,0.0004093157,0.0146922,0.008388324,0.06126565],"study_design_scores_gemma":[0.0005163258,0.001401168,0.9632545,0.0003486993,0.001062237,0.0006825771,0.002151359,0.00519393,0.0008162845,0.00992193,0.01458362,0.00006731669],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9736703,0.005044034,0.0006890242,0.001771731,0.00003336964,0.00003171555,0.002607878,0.0000203396,0.01613172],"genre_scores_gemma":[0.9948388,0.002117127,0.0001207102,0.0001496259,0.00005959428,0.00001373757,0.001336271,0.000006716162,0.001357437],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01284238,"threshold_uncertainty_score":0.04296207,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2082560103","doi":"10.1002/hec.698","title":"The importance of being first: evidence from Canadian generic pharmaceuticals","year":2002,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":89,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Calgary","funders":"Health Canada","keywords":"Competitor analysis; Market share; Generic drug; Business; Drug industry; Drug approval; Industrial organization; Economics; Marketing; Public economics; Drug; Medicine; Pharmacology; Engineering","authors":[{"name":"Aidan Hollis","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1884296525869112,"gpt":0.334590399991603,"spread":0.1461607474046918,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003988346,0.0004826282,0.0008419533,0.00303196,0.002689304,0.003064296,0.001424571,0.001452132,0.009664281],"category_scores_gemma":[0.04368034,0.0004205864,0.0008382063,0.007197613,0.002263589,0.001162018,0.001649018,0.001739566,0.00040933],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01770211,"about_ca_system_score_gemma":0.02170926,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9690133,"about_ca_topic_score_gemma":0.9727949,"domain_scores_codex":[0.9940405,0.0006451418,0.0002660002,0.000545239,0.003207524,0.001295544],"domain_scores_gemma":[0.9577726,0.01456442,0.01543514,0.001451615,0.007876648,0.002899675],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001980758,0.0001874412,0.9177313,0.0009900094,0.0007519731,0.000744448,0.003481333,0.0009273362,0.0002037361,0.004779178,0.01251386,0.05570876],"study_design_scores_gemma":[0.00006490717,0.0000780466,0.9877757,0.0001900954,0.0003446886,0.0001359704,0.001611906,0.0001776137,0.0001695768,0.0002942362,0.009121489,0.00003571343],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8921044,0.02818293,0.000368422,0.009854726,0.0001021809,0.0001191586,0.007863609,0.00002480088,0.06137975],"genre_scores_gemma":[0.9859673,0.009013784,0.0001166113,0.0007953112,0.00005722689,0.000009868076,0.001902299,0.00001066861,0.002126957],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03098667,"threshold_uncertainty_score":0.1284385,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2046647352","doi":"10.1097/mlr.0b013e31818af850","title":"Is There a Relationship Between Patient Beliefs or Communication About Generic Drugs and Medication Utilization?","year":2009,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":88,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging; Canadian Institutes of Health Research","keywords":"Pharmacy; Scale (ratio); Medical prescription; Medicine; Generic drug; Family medicine; Health communication; Drug; Actuarial science; Psychology; Nursing; Business; Pharmacology","authors":[{"name":"William H. Shrank","is_ca":false},{"name":"Suzanne M. Cadarette","is_ca":false},{"name":"Emily R. Cox","is_ca":false},{"name":"Michael A. Fischer","is_ca":false},{"name":"Jyotsna Mehta","is_ca":false},{"name":"Alan Brookhart","is_ca":false},{"name":"Jerry Avorn","is_ca":false},{"name":"Niteesh K. Choudhry","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1341146675802448,"gpt":0.3455821168426299,"spread":0.2114674492623851,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004597127,0.000250301,0.0002834104,0.0007701897,0.00022524,0.001035471,0.0004095686,0.001314787,0.006972876],"category_scores_gemma":[0.03950105,0.0002515218,0.0006637252,0.0009797459,0.001080458,0.00100381,0.0005680496,0.001098574,0.0003859052],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004820617,"about_ca_system_score_gemma":0.0006887364,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002133265,"about_ca_topic_score_gemma":0.001913346,"domain_scores_codex":[0.9970558,0.001764605,0.0002263404,0.0002565188,0.0004304884,0.0002662636],"domain_scores_gemma":[0.9535502,0.03172379,0.01143007,0.0006921697,0.001128713,0.001475031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00009980278,0.00006298488,0.9961349,0.00003106826,0.00007483943,0.00002571291,0.0001372299,0.00004355111,0.00002791182,0.00003323904,0.00007412676,0.003254686],"study_design_scores_gemma":[0.00001227208,0.000184961,0.9983603,0.00004018596,0.00006866656,0.000156931,0.0003116499,0.0005812029,0.00003764343,0.0001244151,0.0001160164,0.000005650461],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995279,0.001086899,0.0003160927,0.00190289,0.00001321455,0.00001195439,0.0001743409,0.000005926529,0.001209696],"genre_scores_gemma":[0.9993176,0.0002297342,0.0001392764,0.0001721266,0.00002555808,0.000007097865,0.00005906863,0.000001021978,0.00004836727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006972876,"threshold_uncertainty_score":0.0243122,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2060894663","doi":"10.1038/clpt.2014.145","title":"Accelerated Access to Innovative Medicines for Patients in Need","year":2014,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":87,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Canada; Institut National d'Excellence en Santé et en Services Sociaux","funders":"Innovative Medicines Initiative; National Comprehensive Cancer Network; European Federation of Pharmaceutical Industries and Associations; Bill and Melinda Gates Foundation","keywords":"Clinical pharmacology; Variety (cybernetics); Access to medicines; Business; Health care; Medicine; Pharmacology; Economic growth; Computer science; Economics; Nursing; Public health","authors":[{"name":"L G Baird","is_ca":false},{"name":"Reiner Banken","is_ca":true},{"name":"H‐G Eichler","is_ca":false},{"name":"Finn Børlum Kristensen","is_ca":false},{"name":"D K Lee","is_ca":true},{"name":"John C. W. Lim","is_ca":false},{"name":"Robyn Lim","is_ca":true},{"name":"Carole Longson","is_ca":false},{"name":"Edmund J. Pezalla","is_ca":false},{"name":"Tomas Salmonson","is_ca":false},{"name":"Dima Samaha","is_ca":true},{"name":"Sean Tunis","is_ca":false},{"name":"Janet Woodcock","is_ca":false},{"name":"Gigi Hirsch","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2719753222378785,"gpt":0.4731631481498151,"spread":0.2011878259119367,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003059832,0.0001491721,0.0002808199,0.00100638,0.0006397286,0.002706076,0.0004475534,0.001651571,0.02886429],"category_scores_gemma":[0.01449944,0.0001424742,0.0007998412,0.0009020886,0.0006559041,0.00220233,0.003046395,0.002319706,0.001513654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001779214,"about_ca_system_score_gemma":0.004256395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002042674,"about_ca_topic_score_gemma":0.00298674,"domain_scores_codex":[0.9980571,0.0009850346,0.0001030476,0.0001241876,0.0003616855,0.0003689053],"domain_scores_gemma":[0.9899635,0.004360581,0.002641277,0.0003889957,0.0008119366,0.001833793],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000877032,0.0009705999,0.1759079,0.001042168,0.0002161993,0.001222391,0.001692913,0.003076801,0.002529415,0.1924619,0.0725409,0.5474618],"study_design_scores_gemma":[0.0009870735,0.001688146,0.3357475,0.001704473,0.0003603631,0.004967878,0.005153098,0.006115436,0.002528184,0.1406887,0.4999349,0.0001242768],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"commentary","genre_scores_codex":[0.4727768,0.01969823,0.01804307,0.3120031,0.0009624783,0.0003653375,0.002053564,0.0003514375,0.1737459],"genre_scores_gemma":[0.9516977,0.01059974,0.00838686,0.01346094,0.002243263,0.0001247359,0.0007034701,0.00005183021,0.01273149],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.02886429,"threshold_uncertainty_score":0.09656066,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1743375347","doi":"10.1111/j.1755-5949.2010.00210.x","title":"Switching from Brand‐Name to Generic Psychotropic Medications: A Literature Review","year":2010,"lang":"en","type":"review","venue":"CNS Neuroscience & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":84,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Lamotrigine; Venlafaxine; Tolerability; Medicine; Psychiatry; Topiramate; Quetiapine; Clonazepam; Cobicistat; Pharmacology; Psychology; Adverse effect; Anxiety; Epilepsy; Schizophrenia (object-oriented programming); Antidepressant","authors":[{"name":"Julie Eve Desmarais","is_ca":true},{"name":"Linda Beauclair","is_ca":true},{"name":"Howard C. Margolese","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1606504007618799,"gpt":0.3863121722456307,"spread":0.2256617714837508,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002967059,0.001361301,0.003505207,0.01804359,0.0006876424,0.001846131,0.002020409,0.001847645,0.005295973],"category_scores_gemma":[0.007438498,0.0007421956,0.002150255,0.02168875,0.000777212,0.003555116,0.0009262079,0.0006691735,0.0008820476],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002392537,"about_ca_system_score_gemma":0.006359833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004166949,"about_ca_topic_score_gemma":0.01045308,"domain_scores_codex":[0.9977149,0.0004805427,0.000947055,0.0002430759,0.0005115239,0.0001029189],"domain_scores_gemma":[0.9925096,0.004518821,0.001645282,0.00009361969,0.001108461,0.0001240987],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00020511,0.0000802171,0.001473768,0.6090201,0.001379387,0.001291566,0.0004112627,0.0002066238,0.0004865745,0.0007765159,0.01212102,0.3725479],"study_design_scores_gemma":[0.000175958,0.0004445291,0.01261514,0.7865713,0.01542623,0.007266807,0.001324665,0.0002628488,0.0006579433,0.001119201,0.174042,0.00009335634],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004717489,0.9987065,0.00005812804,0.0001987766,0.00007150793,0.00003993372,0.0000688653,0.000004560071,0.0003800948],"genre_scores_gemma":[0.002386015,0.9969071,0.000249109,0.0001980385,0.00005359569,0.00004974578,0.00007478631,0.000001313822,0.00008030833],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01804359,"threshold_uncertainty_score":0.01771677,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}